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Abstract
P-glycoprotein (P-gp/ABCB1) is an important efflux drug transporter affecting the disposition
of 50% of marketed drugs. Cell monolayer permeability assays are the gold standard for
assessing P-gp-drug interactions in vitro, but inter-laboratory assay differences produce
heterogeneous results. We compared the validity and sensitivity of traditional assay metrics
of efflux transport (unidirectional apparent permeability and efflux ratio) with a modeled
clearance metric, CLP-gp and hypothesized that CLP-gp would be superior. Cell monolayers
heterologously transfected with ABCB1, and 1,25(OH)2D3-modulated ABCB1 in cells served
as experimental models. P-gp expression was quantified by western blot and bidirectional
[3H]-digoxin transcellular flux was measured. Linear regression analyses were performed for
P-gp expression versus each P-gp activity metric. The validity and sensitivity of modeled
clearance was comparable to traditional metrics within a cell type, but was superior across
different cell types. In conclusion, CLP-gp offers a physiologically-relevant and universally
acceptable metric for efflux transport activity.
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Chapter 1
Introduction
1.1

Pharmacokinetics

Pharmaceuticals agents act on various molecular targets throughout the body. A
particular concentration of unbound drug must be achieved at a given site of action for a
drug to produce its intended pharmacological effect. However, a much lower level of
drug will not produce the desired therapeutic effect and a much higher level can be
associated with toxicity. Therefore, drug concentration present at different sites is a
critical determinant of the pharmacological efficacy of any drug therapy.
Pharmacokinetics (PK) is a branch of pharmacology that examines the interplay between
drug properties and physiological processes in the body to dictate circulating drug levels
over time.
1.1.1 Absorption, distribution, metabolism and elimination (ADME)
The pharmacokinetic processes can be broken down into absorption, distribution,
metabolism, and elimination (excretion), given the common acronym ADME. Absorption
refers to the pharmacokinetic processes involved in the movement of administered drugs
into the systemic circulation and the bioavailability of a drug describes the fraction of an
administered dose that actually reaches the systemic circulation unchanged. Any drug
that is not injected directly into the blood stream by intravenous (IV) administration must
cross at least one cell membrane barrier to enter the circulation. Permeability across any
cell membrane is a function of the physiochemical properties of both the drug (i.e.
molecular size, shape, ionization, and lipid solubility) and the membrane (e.g. protein
channels and drug transporters). Drug movement may occur via passive diffusion
through the lipid membrane and/or via carrier-mediated transport. Many primary active
transporter proteins show unidirectional transport activity and depending on their
orientation in polarized epithelia, they may either facilitate or oppose absorption from the
GI tract and other body compartments. Since the vast majority of drugs are administered
by oral dose (per os), factors affecting GI drug absorption are of particular therapeutic
concern.
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During the distribution phase, a drug achieves a certain concentration in the blood
(CPlasma), which changes over time. Transporters expressed in various tissues of the body
may play a role in the selective accumulation and distribution of drugs into target tissues.
The term volume of distribution (Vd) describes overall how well a drug distributes from
the blood into body tissues.
Chemical modification, or metabolism, of parent drugs occurs primarily in the liver to
produce metabolites of increased polarity. Many of the metabolic reactions are mediated
by a class of heme-containing enzymes found in the hepatocyte endoplasmic reticulum,
which are known as the cytochrome P450 superfamily of oxygenases (CYP). There are
57 genes and over 59 pseudogenes in humans, divided among 18 families and 43
subfamilies by sequence homology (1). The CYP 1 to 3 families are the biggest
contributors to drug metabolism in humans. In particular, cytochrome P450 family 3,
subfamily A, member 4 (CYP3A4) metabolizes as many as 50 percent of drugs on the
market and is the most clinically relevant of the CYP isoforms (1;2).
Polar parent drugs and metabolites are eliminated by passive filtration into the urine or by
carrier-mediated transport into the urine or stool. Plasma clearance (CLplasma) represents
the irreversible removal of a drug from the plasma, as a volume cleared per unit time, and
it is the summation of elimination processes in the body. CLplasma can be determined
from the area under the plasma concentration curve (AUC) following a single IV dose as
Dose/AUC. The half-life (t1/2) of a drug – the amount of time it takes for drug
concentrations in blood to decline by 50 percent – also relates to the plasma clearance
and volume of distribution by the following relationship:


t1/2 = 0.693 × 

[1.1]

For multiple dosing, CPlasma oscillates with each dose until an average steady-state plasma
concentration (Cpss) is reached when the rate of administration is equal to the rate of
elimination.
At steady state:
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= CL × Cpss

[1.2]

where,
Rate of drug administration =




Rate of drug elimination = CLplasma × Cpss

[1.3]
[1.4]

The drug dose (D) and dosing frequency (τ) are selected inversely proportional to the
CLplasma, such that the CPss of a drug remains within the therapeutic range.
1.1.2 Interindividual variation in ADME
As suggested in Section 1.1.1, drug transporters and drug metabolizing enzymes (DMEs)
play a critical role in ADME processes. Accordingly population variations in these
ADME proteins can account for striking differences observed in the way that certain
individuals or populations handle a particular drug (3; 4). For many drugs,
pharmacokinetics and thus optimal dosing can vary significantly between patients; the
standard dosing regimen may fail to reach a therapeutic level in some individuals or may
exhibit dose-dependent toxicity in others. This is of particular concern for drugs with a
narrow therapeutic index (the ratio between the therapeutic dose and the toxic dose).
Both genetic and environmental factors can contribute to the variations in ADME protein
activity and expression that are responsible for population pharmacokinetic variability.
Genetic polymorphisms are DNA sequence variants that naturally occur at a given
genome locus in more than 1% of the population and are not due to recurrent mutations.
They may be in the form of a single substituted, inserted or deleted nucleotide base (a
single nucleotide polymorphism or SNP), or a larger segment of DNA that is present in
irregular frequency (copy number variation or CNV). Polymorphisms appear broadly
throughout the human genome and many polymorphic sites have been shown to impact
the expression and/or function of a variety of gene products, including several key drug
metabolizing enzymes and transporters (4-6).
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Exposure to xenobiotics can also produce significant interindividual variation in the
activity and expression of drug metabolizing enzymes and drug transporters. A drug
interaction is said to have occurred when the presence of foods, dietary supplements,
other drugs or drug diluents cause variation in drug response. Co-administered
compounds may bind an enzyme or transporter to cause a concentration-dependent
decrease in enzyme or transporter activity. They may also inhibit or induce ADME
protein activity by modulating gene expression via transcriptional mechanisms involving
nuclear hormone receptors. Those interactions that result specifically from the presence
of a second drug, termed drug-drug interactions (DDIs), have been a recognized obstacle
to successful drug therapy since the 1960s (7; 8).
As a result of the ever-growing list of clinically relevant genetic polymorphisms and
drug-drug interactions, many drug regulatory agencies, including the FDA, offer
recommendations for routine assessment and management of polymorphisms and DDIs
during drug discovery, drug development and clinical drug use. Pharmacogenomic and
drug-drug interaction studies have become critical in the selection of new chemical
entities with desirable pharmacokinetics and in elucidating the mechanisms underlying
observed preclinical and clinical drug levels. It is important to know how extensively
particular polymorphisms and DDIs alter the expression and or activity of ADME
proteins and to know how this information translates into the clinical setting.
1.2

Transporters
1.2.1 Transporters

1.2.1.1 Physiological and pharmacological role
Transporters are transmembrane proteins that are expressed in the various tissues of the
body to facilitate the movement of important endogenous compounds across the cell
plasma membrane. Endogenous substrates include inorganic ions, amino acids, sugars
and nucleotides. However, substrate specificity is not limited to physiological
compounds. Many transporters, in fact, recognize a variety of structurally diverse
xenobiotics including environmental compounds, dietary compounds, drugs and drug
metabolites. Transporters can thus have an important role in pharmacokinetics and
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therapeutic efficacy and can be a mechanism for interindividual variability, interspecies
variability and drug-drug interactions.
1.2.1.2 Structure and function
Due to their hydrophobic nature, relatively low abundance, and inherently flexible
structure, molecular identification of transporters was difficult to accomplish until the
development of modern expression cloning techniques in the early 1990s. Three
dimensional crystal structures have only been achieved at atomic resolution for a limited
number of transporters thus far. Nonetheless, drug transporters can be categorized
molecularly into two major groups: the ATP-binding cassette (ABC) and the solute
carrier (SLC) superfamilies of transporters. In humans, the ABC superfamily is
comprised of 7 families with 48 known members (9; 10). These transporters have an
ATP-binding domain that binds and hydrolyzes ATP to power active transport of
substrates against a concentration gradient. The most well characterized members of this
superfamily are the ABCB1 and ABCG2 members known as P-glycoprotein/multidrug
resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP) respectively.
The SLC superfamily is comprised of 55 families, with approximately 362 known
members (11). These transporters do not have an ATP-binding domain, but instead use an
ion gradient to power active transport of their substrates. Important SLC drug transporters
are the organic anion-transporting polypeptide 1B1 (OATP1B1), the organic aniontransporting polypeptide 1B3 (OATP1B3), the organic anion transporter 1 (OAT1) the
organic anion transporter 3 (OAT3), and the organic cation transporter 2 (OCT2) (12).
Respectively, these transporters are the SLCO1B1, SLCO1B3, SLC22A6, SLC22A8, and
SLC22A2 members of the solute-carrier transporter family.
In addition to molecular categorization, transporters can also be grouped by their
function. Uptake transporters move substrates from the extra cellular space into the cell
cytoplasm. This is more common among SLC drug transporters. Conversely, efflux
transporters extrude substrates into the extracellular environment, which is more common
among, but not limited to, the ABC drug transporters. Quite often, uptake and efflux
transporters coordinate activity for the asymmetrical transport of endogenous compounds,
drugs, or toxins across an epithelial or endothelial barrier of cells (13). This kind of
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vectorial transport is how polarized cells can facilitate passage of both hydrophilic and
lipophilic compounds across biological membranes to contribute to drug absorption,
distribution and elimination, as alluded to in Section 1.1.1.
Vectorial transport is possible because of overlap in the substrate specificities of different
uptake and efflux transporters. For example, in a model of the blood to bile hepatic
secretion of organic anions, Cui et al. showed vectorial transport of sulfobromophthalein
(BSP) across a membrane of polarized Madin-Darby canine kidney (MDCK) cells that
were double-transfected with organic anion transporter 1B3 (OATP1B3; SLC member
SLCO1B3) and multidrug resistance-associated protein 2 (MRP2; ABC member ABCC2)
(14). The cells demonstrated basolateral OATP1B3 uptake and subsequent apical MRP2
efflux of BSP. For highly lipophilic compounds with sufficient membrane permeability,
unidirectional ABC efflux transporters are able to achieve vectorial transport across a
polarized plasma membrane without coordinated influx by an uptake transporter (15).
But, coordination of uptake and efflux transporters is necessary for the vectorial transport
of more hydrophilic compounds. Consequently, a variety of different uptake and efflux
transporters are expressed on either membrane of the polarized epithelial or endothelial
cells of several organs. This includes intestinal epithelia, hepatocyte epithelia, kidney
proximal tubule epithelia, and endothelial cells of the blood-brain barrier.
1.2.2 P-glycoprotein/MDR1
The role of transporters in pharmacokinetics is a maturing area of investigation and the
important pharmacokinetic impacts of many transporters have yet to be fully elucidated.
P-glycoprotein was among the first transporters to be studied; it is the most well
characterized transporter to date and it was the first transporter protein recommended for
regular pharmacokinetic testing by the FDA (16-18).
1.2.2.1 Discovery and Cloning of P-gp
In 1960, acquired resistance to actinomycin D was reported in HeLa cell lines (19) and
then later in Chinese hamster ovary cells (20). These cells were shown to possess
multidrug resistance and subsequently Dano et al. demonstrated active efflux of
daunomycin in the cells by a proposed efflux pump (21). Juliano and Ling named the
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pump permeability-glycoprotein (P-glycoprotein or P-gp), for its ability to alter the
permeability of mutant cells (22). In the following decade, Riordan and his group were
the first to clone the gene for P-glycoprotein (23). By 1987, it became apparent that P-gp
is physiologically expressed in normal human excretory and barrier tissues, such as the
intestine, liver, kidney and the blood brain barrier (24-34). Ultimately, P-gp was defined
as a primary efflux pump that uses the energy from ATP hydrolysis to actively extrude its
substrates from cells (35). The gene for the transporter was originally called multidrug
resistance gene (MDR1) because of the multidrug resistance phenotype it conferred to
tumour cells, but has since been classified as ABCB1 (member 1 of the B subfamily in the
ATP-binding cassette transporter superfamily). In 2009, the P-gp x-ray crystal structure
was revealed for better characterization of substrate-binding and solute translocation
mechanism of this key drug transporter (36). Today, P-gp remains the most well studied
and well characterized drug transporter in humans.
1.2.2.2 Biochemistry (structure, substrates and function)
P-gp is a 170 kDA protein composed of 1280 amino acids. Its quaternary protein
structure is organized as 2 homologous halves, each with an intracellular nucleotide
binding domain and a bundle of 6 hydrophobic transmembrane α-helices (36-39). Nglycosylation occurs at the first extracellular loop and the 2 halves are linked by a highly
charged and phosphorylated region. The linking region contains signature motifs that are
characteristic of the ABC transporter family. Collectively, the transmembrane segments
form a central internal cavity where multiple sites are found for substrate and modulator
binding (36). This binding pocket is substantially larger than most transporters and can
even accommodate 2 substrates simultaneously (40). Additionally, substrate binding in
the pocket produces size- and shape-dependent conformational changes of the
transmembrane segments, alluding to an induced-fit for substrate binding (40). Taken
together, some of these structural characteristics may explain the incredibly broad
substrate specificity observed for the P-gp transporter.
P-gp transports a wide variety of structurally and functionally diverse compounds
including: opioids, steroids, antibiotics, calcium-channel blockers, chemotherapeutics,
immunosuppressants, anti-HIV drugs, linear and cyclic peptides, ionophores, bilirubin,
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and many others (41) (Table 1.1). Many P-gp substrates are nonpolar, weakly
amphipathic compounds and contain planar aromatic rings and positively charged tertiary
nitrogens. However, there are no clearly defined recognition elements that are highly
conserved among all P-gp substrates and modulators. It is worth noting though, that many
of P-gp’s substrates are also found to be substrates of the CYP3A4 enzyme, suggesting
MDR1 and CYP3A4 have a synergistic protective role to reduce the intestinal absorption
of xenobiotics (42-44; 5).
P-glycoprotein functions as a unidirectional lipid flipase (45). Substrate binding initiates
ATP-binding, which causes dimerization of the nucleotide binding domains (NBD),
which results in a large structural change of the transporter protein into its outward facing
conformation. The substrate is then released into extracellular space as ATP is
hydrolyzed. Simultaneously, the ATP hydrolysis disrupts the NBD dimerization, hence
causing P-gp to revert back to its original inward facing conformation (46). In P-gp’s
active conformation, the internal cavity formed by the transmembrane helices, is oriented
inward, open to both the cytoplasm and the inner membrane leaflet (47). Substrates in the
outer membrane leaflet and the extracellular space do not have direct access to the pocket
(36; 48) and P-gp extrudes its substrates directly from the inner leaflet; this is a common
feature among transporters with a binding site located in a transmembrane domain of αhelices. Many P-gp substrates readily partition into the plasma membrane and require
association with lipids for drug-stimulated ATPase activity (49).
1.2.2.3 Tissue expression and role in absorption, distribution and elimination
Cells that express P-gp extrude substrates directly from the membrane, thereby
preventing substrate drugs and toxins from entering the cell. Immunohistochemical
analysis has indicated that human P-gp is expressed typically at the apical membrane of
polarized cells in several tissues with barrier functions (e.g. small intestine, blood-brain
barrier, blood-testis barrier, blood-ovarian barrier and placenta) or secretory functions
(e.g. liver, kidney and adrenal gland) (50; 51; 44; 52-54). The greatest MDR1 expression
is found in the intestinal epithelia; again indicating an important role of P-gp in
modulating intestinal absorption. Indeed, induction of intestinal P-gp by the antibiotic
rifampin correlated with a significant decrease in the AUC of orally administered
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digoxin, a P-gp substrate, in humans (55). Beyond this, P-gp is apically expressed in liver
and kidney epithelia, and on the blood side of brain capillary endothelial cells. It plays a
significant role in the biliary and urinary excretion of various drugs and is known to limit
central nervous system (CNS) penetration, as part of the blood-brain barrier (26; 56).
Despite the broad activity of P-gp, the Collie dog breed and a substrain of the CF-1
mouse are viable and fertile even though they are both naturally devoid of any P-gp
expression (57-59). From this it can be concluded, in dogs and mice at least, that P-gp
does not carry an essential physiological function. However, no human null allele has
ever been reported for P-glycoprotein to date. Also of note, collie dogs and CF-1 mice do
show significantly heightened sensitivity to drug and xenobiotic exposure; this once
again emphasizing the important protective role of P-gp in the body (58-60).
1.2.2.4 Gene regulation
For decades, it has been well appreciated that the body mounts an adaptive response
when exposed to xenobiotics, which is meant to limit exposure to toxic compounds.
Indeed, in 1963 Cucinell et al. first reported decreased concentrations of phenytoin and
coumarin in humans treated with phenobarbital; likely in response to upregulation of drug
metabolizing enzymes (61-63). This kind of ADME protein regulation occurs via ligandactivated nuclear receptor signaling. In the case of most nuclear receptors, the receptor
binds its ligand in the cytoplasm and then translocates to the nucleus, where it forms a
heterodimer with the 9-cis retinoic acid receptor (RXR). The formed heterodimer
complex may bind in the regulatory region of a given ADME protein gene, thereby
affecting the binding and recruitment of co-repressor and co-activator proteins, which
suppress and stimulate gene transcription respectively (64).
The transcription of many drug metabolizing enzymes has been shown to be modulated
in response to xenobiotic ligands that bind the nuclear receptors: Pregnane X Receptor
(PXR) (65-69), Constitutive Androstane Receptor (CAR) (70-73), Vitamin D Receptor
(VDR) (74; 75), Farnesoid X Receptor (FXR) (76-78) and others.
It is only in the past 2 decades or so that regulation of drug transporters by the same
nuclear receptor mechanisms has gained attention as part of a coordinated response to
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xenobiotic toxic exposure. The P-gp transporter was shown to be regulated by PXR,
similar to CYP3A4 (43). Both PXR and CAR binding sites are located in an ABCB1
regulatory region 8 kb upstream of the MDR1 gene transcription start site (80; 81). P-gp
has also been shown to be regulated by Vitamin D. When testing for substances that can
induce CYP3A4 expression in Caco-2 cells, Schmiedlin-ren et al. observed an increase in
P-gp expression after treating cells with 0.05 µM – 1 µM 1,25(OH)2D3, and ≥ 0.5 µM and
≥ 2.5 µM 25-(OH)-D3 (82). Thummel et al. later demonstrated similar vitamin D
modulation of P-gp in Caco-2 cells and LS180 human colon carcinoma cells by 50-1000
nM 1,25(OH)2D3; with a lower limit of induction at 1 nM and an upper limit at 250 nM
(83). Eventually the vitamin D response elements were identified in the human MDR1
promoter between -7880 and -7810 bp upstream of the MDR1 gene, where the
VDR/RXRα heterodimer binds to induce transcription (84). Fan et al. has since
confirmed that vitamin D and associated analogues induce P-gp mRNA, protein, and
transport activity in a human colorectal adenocarcinoma (Caco-2) cell monolayers (85).
1.2.2.5 Relevance of P-gp to clinical pharmacology
A large number of chemically diverse drugs have been demonstrated to interact with P-gp
(Tables 1.1 and 1.2) and thus P-gp has the potential to contribute to a great many
clinically significant drug-drug interactions. For example, in a study of healthy
volunteers, Schwarz et al. showed respectively a 52% and 26% increase in the AUC and
peak plasma concentration of a prototypical P-gp substrate, talinolol, in response to
concomitant administration of the P-gp inhibitor erythromycin (86). This study
notwithstanding though, much of the evidence for clinical drug interactions mediated by
P-gp is derived indirectly from in vitro studies or from animal studies; and few clinically
relevant DDIs have actually been attributed solely to P-gp. One significant reason for this
is the extensive overlap in substrate selectivity, tissue localization, and gene modulation
profile that is shared between MDR1 and CYP3A4 (87). It can be difficult to distinguish
the in vivo contributions of metabolism and transport to DDIs; and metabolism is often
assumed the major cause of DDI, particularly for substrates with fair or extensive
metabolism. However, DDIs involving poorly metabolized P-gp substrates and potent
and selective P-gp modulators have been linked more unambiguously to P-gp (88; 55;
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Table 0.1. P-glycoprotein subtrates.
Substrate
Anticancer agents
Actinomycin D
Daunorubicin
Docetaxel
Doxorubicin
Etoposide
Imatinib
Irinotecan
Mitomycin C
Mitoxantrone
Paclitaxel
Teniposide
Topotecan
Vinblastine
Vincristine
Antihypertensive agents
Celiprolol
Diltiazem
Losartan
Talinolol
Antiarrhythmics
Digoxin
Quinidine
Verapamil
Antiplatelet agents
Clopidogrel
Ticagrelor
Glucocorticoids
Aldosterone
Cortisol
Dexamethasone
Methylprednisolone
Oral anticoagulants
Warfarin
Dabigatran
Rivaroxaban
Apixaban
Edoxaban
Miscellaneous
Atrovastatin
Colchicine
Fexofenadine
Ivermectin
Loperamide
Melfoquine
Rhodamine 123
Terfenadine
Vecuronium
Antiviral agents
Amprenavir

References
Jette et al., 1995
Sharpiro and Ling, 1998
Wils et al., 1994
Sharpiro and Ling, 1998
Sharpiro and Ling, 1998
Widmer et al., 2003
Arimori et al., 2003
Relling, 1996
Relling, 1996
Sparreboom et al., 1997
Relling, 1996
Relling, 1996
Wils et al., 1994
Relling, 1996
Karlsson et al., 1993
Saeki et al., 1993
Soldner et al., 2000
Wetterich et al., 1996
de Lannoy and Silverman, 1992
Kim et al., 1999
Kim, 2002
Taubert et al., 2006
Teng et al., 2010
Ueda et al., 1992
Ueda et al., 1992
Ueda et al., 1992
Saitoh et al., 1998
Schulman et al., 2010
Walenga and Adiguzel, 2010
Gnoth et al., 2011
Warson et al., 2011
Mendell et al., 2011
Wu et al., 2000
Kim, 2002
Cvetkovic et al., 1999
Didier and Loof, 1995
Schinkel et al., 1996
Pham et al., 2000
Kim, 2002
Kim et al., 1999
Smit et al., 1998
Polli et al., 1999
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Indinavir
Nelfinavir
Ritonavir
Saquinavir
Antibiotics
Erythromycin
Levofloxacin
Rifampin
Sparfloxacin
Tetracycline
Antimycotics
Intraconazole
Immunosuppressants
Cyclosporine
Sirolimus
Tacrolimus
Valspodar
Antidepressants
Amitriptyline
Antiepileptics
Phenobarbital
Phenytoin
Antiacids
Cimetidine
Ranitidine
Opioids
Morphine
Antiemetics
Domperidon
Ondansetron

Kim et al., 1998
Kim et al., 1998
Kim et al., 1998
Kim et al., 1998
Schuetz et al., 1998
Ito et al., 1997
Schuetz et al., 1996
Tamai et al., 2000
Kavallaris et al., 1993
Miyama et al., 1998
Schinkel et al., 1996
Paine et al., 2002
Saeki et al., 1993
Tai, 2000
Uhr et al., 2000
Potschka et al., 2002
Schinkel et al., 1996
Collett et al., 1999
Collett et al., 1999
Callagan and Riordan, 1993
Schinkel et al., 1996
Schinkel et al., 1996
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Table 0.2. Drugs shown in clinical and/or in vitro study to affect the pharmacokinetics of
a P-gp probe substrate by inhibition or induction of P-gp.
Interacting Drug
Antihypertensive
agents
Carvedilol
Nicardipine
Reserpine
Antiarrhythmics
Amiodarone
Porpafenone
Quinidine
Verapamil
Glucocorticoids
Dexamethasone
Miscellaneous
Atrovastatin
Bromocriptine
Dipyridamole
Emetine
Melfoquine

Inhibitor/Inducer

Substrate(s)

References

Inhibitor

kakumoto et al., 2003

Inhibitor
Inhibitor

vinblastine, paclitaxel,
doxorubicin, daunorubicin
daunorubicin, digoxin
ATP hydrolysis assay

Inhibitor
Inhibitor
Inhibitor
Inhibitor

digoxin
digoxin
digoxin
digoxin

Kakumoto et al., 2002
Woodland et al., 1997
Fromm et al., 1999
Pauli-Magnus et al.,
2000

Inducer

indinavir

Lin et al., 1999

Inhibitor
Inhibitor
Inhibitor
Inhibitor
Inhibitor

boyd et al., 2000
Orlowski et al., 1998
Verstuyft et al., 2003
Wang et al., 2001
Riffkin et al., 1996

Katoh et al., 2000
Wang et al., 2001

Progesterone
Retinoic acid
Spironolactone
Antiviral agents
Amprenavir
Indinavir
Nelfinavir
Ritonavir

Inhibitor
Inducer
Inhibitor

digoxin
vincristine
digoxin
ATP hydrolysis assay
vinblastine, fluo-3 acetomethoxy
ester, rhodamine 123
vinblastine
vinblastine, colchicine
digoxin

Inhibitor
Inhibitor/Inducer
Inhibitor/Inducer
Inhibitor

digoxin

Saquinavir
Antibiotics
Clarithromycin
Erythromycin
Rifampin
Antimycotics
Intraconazole

Inhibitor

digoxin

Reinhard et al., 2004;
Schmitt et al. 2010
Schmitt et al. 2010

Inhibitor
Inhibitor
Inducer

digoxin
digoxin
digoxin

Wakasugi et al., 1998
Kim et al., 1999
Greiner et al., 2002

Inhibitor

Takara et al., 1999

Ketoconazole
Immunosuppressants
Cyclosporine
Sirolimus
Tacrolimus
Valspodar
Antidepressants
Fluoxetine
Paroxetine
Sertraline

Inhibitor

vinblastine, daunorubicin,
dauxorubicin
rhodamine 123

Inhibitor
Inhibitor
Inhibitor
Inhibitor

rhodamine 123
digoxin
vincristine
N-methyl-quinidine

Yacyshyn et al., 1996
Minocha et al., 2012
Kochi et al., 1999
PSC 833

Inhibitor
Inhibitor
Inhibitor

digoxin
calcein-AM
calcein-AM

Parianteet al., 2009
Weiss et al., 2003
Weiss et al., 2003

Bernes et al., 1996
Elhafny et al., 1997
Nakamura et al., 2001

Takano et al., 1998
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St John’s wort
Neuroleptics
Chloropromazine
Flupenthixol
Phenothiazine
Opioids
Methadone

Inducer

digoxin

Durr et al., 2000

Inhibitor
Inhibitor
Inducer

verapamil
iodoarylazidoprazosin
vincristine

Saitoh and Aungst, 1995
Maki et al., 2003
Watanabe et al., 1995

Inhibitor

vinblastine

Morphine
Pentazocine

Inducer
Inhibitor

expression
vinblastine

Callaghan and Riordan,
1993
Aquilante et al., 2000
Callaghan and Riordan,
1993
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Table 0.3. Genetic polymorphisms in MDR1 with clinically observed PK effects.
SNP

Drug

Parameter

Effect

Reference

C3435T (Exon 26)

Digoxin (oral, ss)

Drug level

Higher for TT

Digoxin (oral, sd)

AUC

Higher for TT

Digoxin (oral, sd)
Digoxin (oral, sd)

AUC(0-4 h), Cmax
AUC

No difference
Lower for TT

Digoxin (oral, sd)

AUC, tmax

Lower for TT

Fexofenadine

AUC

No difference

Fexofenadine
Nelfinavir
Cyclosporine

AUC
Drug level
Trough level

Lower for TT
Lower for TT
No difference

Cyclosporine

AUC, Cmax, tmax

No difference

Cyclosporine
Cyclosporine

AUC, Cmax
AUC(0-4 h)

Tacrolimus

Drug level

Lower for CT/TT
Higher for TT
(trend)
Higher for TT

Hoffmeyer et al.,
2000
Verstuyft et al.,
2003
Gerloff et al., 2002
Sakaeda et al.,
2001
Horinouchi et al.,
2002
Drescher et al.,
2002
Kim et al., 2001
Fellay et al., 2002
von Ahsen et al.,
2001
Min and Ellingrod,
2002
Yates et al., 2003
Balram et al., 2003

Tacrolimus
Tacrolimus

Drug level
Drug level

Higher for TT/CT
No difference

Tacrolimus
Tacrolimus

No difference
No difference

Nortriptyline

Drug level
Tacrolimus induced
neurotoxicity
Drug level

Talinolol

AUC

No difference

Loperamide

No difference

Dicloxacillin

Cmax, AUC, CNS
effects
Drug level

Docetaxel
Phenytoin
Digoxin (oral, sd)

Clearance
Drug level
AUC

No difference
Higher for TT
Higher for TT

Digoxin (oral, sd)
Digoxin (oral, sd)

AUC(0-4h), Cmax
AUC, tmax

No difference
Lower for TT

Digoxin (oral-iv, sd)
Fexofenadine
Tacrolimus
Tacrolimus

Bioavailability
AUC
Drug level
Drug level

Higher for TT
Lower for TT
Higher for TT/GT
Higher for TT

Tacrolimus

Drug level, dose
ratio

No difference

G2677T/A (Exon
21)

No difference

No difference

Macphee et al.,
2002
Zheng et al., 2003
Anglicheau et al.,
2003
Goto et al., 2002
Yamauchi et al.,
2002
Roberts et al.,
2002
Siegmund et al.,
2002
Pauli-Magnus et
al., 2003
Putnam et al.,
2003
Goh et al., 2002
Kerb et al., 2001
Verstuyft et al.,
2003
Gerloff et al., 2002
Horinouchi et al.,
2002
Kurata et al., 2002
Kim et al., 2001
Zheng et al., 2003
Anglicheau et al.,
2003
Goto et al., 2002
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Tacrolimus
Talinolol
ss, steady state; sd, single dose

Tacrolimus induced
neurotoxicity
AUC

Higher for TT
(trend)
Slightly higher for
TA/TT

Yamauchi et al.,
2002
Siegmund et al.
2002

17

89).
In recent decades, DDIs with selective P-gp inhibitors have been exploited to boost the
efficacy of anticancer drugs. The idea was first introduced in 1981 when Tsuruo et al.
discovered that verapamil increased the sensitivity of multi-drug resistant leukemia cells
to chemotherapeutic drugs in vitro (90). As a consequence of this study, additional work
has been put into designing potent and selective P-gp inhibitors to be used as adjuncts to
chemotherapy. In one Phase I clinical study, there was an 89% increase in AUC and 46%
decrease in clearance of etoposide in response to intravenous infusion of the selective Pgp inhibitor PSC-833 (91). Today, P-gp inhibitors may also be applied to enhancing drug
penetration through the blood-brain-, blood-cerebrospinal-, and maternal-fetal-barriers as
well (92-94).
Beyond DDIs, different polymorphisms of the MDR1 gene exist in the population with
varied functional consequences (Table 1.3). Kioka et al. were the first to identify MDR1
polymorphisms in 1989 from in vitro study of cancer cells; since that time over 2 dozen
MDR1 SNPs have been reported with different frequencies across ethnic populations (9598). A cytosine to thymine SNP at position 3435 in exon 26 (C3435T) was the first
polymorphism reported to affect P-gp protein expression, although this SNP does not
alter the encoded amino acid – thus referred to as a synonymous SNP (99). Healthy
Caucasian subjects with the variant T allele were shown to have a 2-fold reduction in
duodenal P-gp expression as compared to subjects with the wild type C allele (99). These
individuals also showed increased plasma concentration of the P-gp probe substrate
digoxin following its oral administration; this suggesting enhanced oral absorption in
individuals with diminished duodenal P-gp expression. Several different studies
confirmed the impact of this polymorphism (100-102). But others have actually reported
the variant allele (3435T) to yield decreased serum digoxin (103; 104), or to have no
clinical effect at all (105). As with DDIs, the clinical impact of P-gp polymorphisms can
be quite ambiguous and complex.
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1.2.2.6 Relevance to drug development
Owing to improvements in CYP molecular biology, to readily available in vitro models,
and to in silico approaches, high-throughput scanning of CYP enzymes has been
increasingly embraced by industry and regulatory agencies for almost 2 decades (106108). As the body of work in the area of drug transporters catches up with DMEs and the
role of drug transport in clinical PK is further elucidated, pre-clinical assessment of
transporter interactions has become an area of growing interest in drug discovery and
development (109-111). An early understanding of P-gp in drug pharmacokinetics
facilitates the recognition of important clinical DDIs and polymorphisms that may greatly
impact the disposition, dosing regimens, therapeutic efficacy and safety of a great number
of drugs and drug candidates (112; 12). Current FDA guidance describes experimental
systems, experimental designs and decision criteria to assess new chemical entities
(NCEs) and drug candidates for P-gp interactions (113). Compounds that demonstrate
significant interaction with P-gp, based on up-to-date in vitro and/or in vivo testing, may
be required to undergo additional studies to demonstrate safety and optimal use, or may
even be withdrawn in extreme cases. Study of P-gp is an integral component of premarket drug development and regulatory review (12; 114; 115) and P-gp testing is
typically carried out, like other PK tests, in parallel to pharmacodynamic studies of drug
response (116). P-gp tests are especially important for drugs that are intended for oral
administration, or are targeted to the CNS. Furthermore, as part of post market drug
monitoring, P-gp interaction studies have elucidated the mechanisms of several reported
drug-drug interactions, population variations, or rare adverse drug events.
1.2.2.7 Animal models
Shortly after the physiological expression of P-glycoprotein in human tissues became
apparent in the late 80s, P-gp was also found to be expressed in the isolated brain
capillaries of mice, rats, pigs and cows (117-120). Various forms of P-gp have also been
reported to express in numerous other species of insects, fish, amphibians, reptiles, birds,
and mammals. Today, closely related homologues of ABCB1 have been cloned and
sequenced in human, mouse, Chinese hamster, dog and other species including,
Caenorhabditis elegans and Drosophila melanogaster (121; 122). In higher mammals P-
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gp forms a small gene family, with only one drug transporting isoform expressed in
humans (MDR1/ABCB1), and two co-operative drug transporter isoforms expressed in
rodents (mdr1/ABCB1a and mdr3/ABCB1b) (123-125).
Recent advancements in transgenic animal models and knock out animals allow us to
study the in vivo role of specific ADME proteins in human PK and drug-drug
interactions. For instance, single and double P-gp knockout mouse models, lacking
ABCB1a and ABCB1b, have been bred for in vivo pharmacokinetic studies. While these
mice do show increased sensitivity to drug and xenobiotic exposure, they are viable and
fertile for study (126). Moreover, although compensatory upregulation of complimentary
enzymes or transporters may somewhat disguise the absence of P-gp in the mice (127), Pgp-deficient animal models provide valuable information about weather a drug is a
substrate or modulator of MDR1 (128-130). As well, these particular knockout models
have proven very useful in assessment of the impact of P-gp on the CNS penetration of
psycho-active drugs. For example, Schinkel et al. compared the disposition of the
veterinary pesticide ivermectin in knockout mice against wild type mice (57; 131). They
saw a 100-fold greater brain ivermectin AUC in mdr1a (-/-) mice as compared to wild
type. The increased brain exposure in the knockout mice resulted in a much greater
neurotoxicity and mortality in the knockout mice versus the wild type mice that had
regular expression of blood-brain-barrier P-glycoprotein.
Of note, caution must be taken when extrapolating the pharmacokinetics in an animal
model to the human situation. Scaling animal pharmacokinetics solely by weight
(allometric scaling) is not always effective due to species differences in a variety of
physiological and biochemical properties, including organ blood perfusion, pH, gastric
emptying time and various other factors. Moreover, species differences in the expression,
localization, regulation and substrate specificity of DMEs and drug transporters can yield
significantly different pharmacokinetics for a drug in humans versus an animal model.
Early studies looked at the resistance profiles of Chinese hamster ovary cells
overexpressing human MDR1 and murine mdr1 and mdr3 genes; the resistance conferred
by MDR1 versus mdr1/3 was significantly different for various MDR drugs, as was the
effect of different P-gp modulators on vinblastine resistance (132). A variety of
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subsequent studies further confirmed species differences for several different P-gp
substrates and modulators (50; 133-135). Although transgenic animal models expressing
humanized proteins are currently available to improve the accuracy of human
extrapolation, most are created for human drug metabolizing enzymes.
1.3

In vitro to in vivo (IVIV) prediction of pharmacokinetics
1.3.1 General scheme

Various transporter and DME interactions and DDIs have led to prescribing restrictions,
market withdrawals, new drug submission rejections and early development terminations,
for many pharmaceutical agents (136). So, it’s not surprising that regulatory bodies,
including the FDA and the European Medicines Agency (EMA), as well as academics are
increasingly concerned about the contributions of key DMEs and transporters to drug
disposition. In vitro to in vivo extrapolation (IVIVE) allows us to characterize the activity
of ADME proteins in vitro, so as to clarify and predict their roles in the in vivo kinetics of
drugs and drug candidates. It helps us to explain and predict the bioavailability, clearance
and tissue distributions of clinically important drugs. For example, a compound that is
identified in vitro as a strong P-gp substrate will likely show a high level of P-gp efflux in
vivo. One in vivo consequence of compounds with efficient efflux by P-gp would be a
significant decrease in oral absorption of the compound, since P-gp is highly expressed in
the intestinal lumen where it actively opposes the absorption of substrate compounds.
Characterizing drug-transporter and drug-enzyme interactions through in vitro studies is
an essential step in understanding drug PK or in anticipating whether or not a drug is
likely to exhibit favourable clinical PK. Certainly, important early decisions in drug
discovery and development (DDD) are based on the interpretation of preclinical in vitro
studies and their implications to in vivo kinetics (116; 137; 136).
1.3.2 Quantitative IVIVE
For quantitative IVIVE, additional information is required about the ADME protein and
about the in vitro and in vivo systems that are being compared (Figure 1.1).
The rate of metabolism for a given enzyme-substrate pair in any in vitro or in vivo
system, is proportional both to the absolute intrinsic activity of that enzyme on its
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substrate and to the total amount of that enzyme expressed in the given system. Likewise,
the rate of carrier-mediated transport for a given transporter-substrate pair in a system, is
proportional to the absolute intrinsic activity and amount of that transporter in the system
(138). Absolute intrinsic activity describes the characteristic efficiency at which an
individual enzyme or transporter turns over substrate. It is a system-independent, inherent
biochemical property of each individual ADME protein and is thus consistent, for a given
protein, across in vitro and in vivo systems. So, it follows that quantitative in vitro to in
vivo extrapolation is accomplished by scaling the amount of enzyme and/or transporter
between systems, with a constant absolute intrinsic activity. Absolute intrinsic activity
can be determined from the in vitro intrinsic activity in a system of known
enzyme/transporter amount. In order to quantify transporter/enzyme amount, functional
units of a system, such as cell number or protein content, are often used as convenient
surrogates for actual transporter/enzyme content.
More sophisticated IVIVE models include information about the in vivo relative
abundances of interacting enzymes and transporters, along with physiological parameters
that dictate enzyme or transporter access to unbound drug (e.g. tissue perfusion rates,
solubility etc.). Physiologically-based pharmacokinetic (PBPK) models have been
developed in the past decades to integrate quantitative description of various
simultaneous and dynamic physiological and pharmacokinetic processes, arranged within
a structural framework that represents the anatomical arrangement of the body. These
models have enjoyed increasing popularity in recent years for their ability to compile and
contextualize a wealth of available in vitro and in vivo data. PBPK models have proven
most useful in the prediction of DDIs, population PK and toxin exposure (139-142).
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Figure 1.1. Simplified general scheme of quantitative IVIVE for hepatically eliminated
drugs. Models are organized as tissue and extracellular compartments (eg. Liver, hepatic
sinusoids, hepatic canaliculi) perfused by blood flow (Q). Movement of unbound drug
into and out of compartments is defined by physiologically relevant, drug-specific
clearance parameters (CLmetabolism; CLtransport) that relate to ADME protein activities. The
clearance parameters are estimated from information about ADME protein expression in
in vivo human tissues; and from information about in vitro ADME protein intrinsic
clearance, normalized to in vitro protein expression. All clearance and flow parameters
interplay dynamically with each other and have differing relative contribution to the
overall PK of a given drug.
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1.3.2.1 Intrinsic clearance in PK modeling
Intrinsic clearance (CLint), a term first coined in 1975 by Wilkinson and Shand, describes
the perfusion-rate-independent clearance of a drug from a system by the cumulative
intrinsic activities of the contributing drug metabolizing enzymes and/or transporters. It is
a cardinal PK parameter in quantitative IVIVE and PBPK modeling. Indeed, scaling of
the intrinsic clearance of in vitro expressed liver enzymes and transporters has shown to
be a robust method of predicting in vivo hepatic drug clearance (143-147). Intrinsic
metabolic clearance (CLint or CLint(Metabolism)) was first described, for hepatic enzyme
kinetics in an isolated hepatocyte in vitro system, as the initial metabolic activity (V0) in
the hepatocytes proportional to the concentration of free drug (Cu) available to the
hepatocytes for metabolism,


CLint =  

[1.5]



Substituting this into the Michaelis-Menten equation for enzyme kinetics (described in
section 1.3.2.2),
v=





[1.6]



gives the following relationship:
CLint =




[1.7]

So, at low substrate concentration (Cu << Km), intrinsic clearance is proportional to Vmax,
inversely proportional to Km and independent of substrate concentration; expressed as,
CLint =



[1.8]

The situations in equations [1.5-1.8] can all be applied analogously to describe the
intrinsic transporter-mediated clearance (CLint or CLint(Transport)) of any drug from a given
compartment. This could be, for instance, applied to describe the in vitro carrier-mediated
uptake of a drug into cultured cells in suspension, or applied to describe the in vivo
secretion of a drug from the liver into the bile.
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Along with CLint(Metabolism) and CLint(Transport), several other physiological parameters (e.g.
blood flow, tissue perfusion) and drug-specific parameters relating to the free drug
concentrations (e.g. plasma protein binding, tissue binding), chemical disposition,
chemical dispersion, and availability for clearance, all factor into determination of the
true in vivo clearance. The so-called “well-stirred” model description for hepatic
metabolic clearance (148) provides a simple example:
CLTotal Liver =

  
  

[1.9]

where, QL is the physiological blood flow to the liver, fu is the fraction of drug in the
blood that is unbound and available for metabolism, and CLint is the overall intrinsic
metabolic clearance of the liver (scaled up from in vitro isolated hepatocytes). The CLint
rate in this model may define the intrinsic activity of one enzyme or, depending on the
drug, it could incorporate the intrinsic activities of a collection of hepatic enzymes that all
contribute to the elimination of a common substrate drug. Note though, that there is no
term for intrinsic carrier-mediated clearance in equation [1.9]; this simplified case
describes a metabolic clearance that is rate-limited by hepatic blood perfusion, in which
unbound drug in the blood bathing the liver establishes instantaneous equilibrium with
the hepatocytes by rapid passive diffusion, such that the intrahepatic and extrahepatic
concentrations of free drug are viewed to be equal. Thus, as unbound drug perfuses the
liver it is immediately available for metabolism at a rate, CLint, that is intrinsic to the liver
enzymes and any active transport is assumed to be negligible. In reality, for many drugs
that display lower passive permeability, carrier-mediated transport into the liver (uptake)
or into the bile (efflux) may rate-limit in vivo liver clearance (149; 150). Kinetic models
that fail to account for important active uptake and/or efflux processes can result in an
under- or over-estimation of system intrinsic clearance parameters (151).
Successful quantitative IVIVE of drug clearance requires proper integration of the
multiple dynamic PK processes of different relative importances. A model of the in vivo
hepatic clearance of enalapril in rats, by Sirianni and Pang (Figure 1.2) (152),
demonstrates some of the interplay between transport and metabolism:
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Figure 1.2. Schematic depiction of the physiological model for liver clearance. The liver
is divided into three compartments: the reservoir (R, or systemic blood compartment),
liver plasma (PL), and liver tissue (L). Q, C, and V represent flow, concentration, and
volume, respectively. The transport clearances for drug from hepatic plasma to tissue and
from tissue to hepatic plasma are characterized by influx (CLinflux) and efflux (CLefflux)
clearances, respectively. Drug metabolism within the liver tissue is characterized by the
intrinsic clearance, CLint,met. Biliary excretion of drug is characterized by the intrinsic
clearance, CLint,sec. Modified from Sirianni and Pang, 1997.
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CLTotal Liver = 
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[1.10]

where, QL is the blood flow to the liver, fu is the fraction of drug in the blood that is
unbound and available for metabolism, CLint,met is the intrinsic metabolic clearance,
CLinflux and CLefflux are respectively the intrinsic influx and intrinsic efflux at the
sinusoidal membrane, and CLint,sec is the secretory intrinsic efflux at the canalicular
membrane. CLTotal Liver in the rat is solved for by writing mass balance equations for the
reservoir, liver plasma, liver tissue, and bile compartments. In order to find agreement
between model simulations and in vivo rat data sets, the in vivo relationships between
many of the interacting parameters had to be defined. For example, since CLinflux and
CLint,met simultaneously contribute to the tissue compartment drug level, Liu and Pang
defined the CLinflux/CLint,met ratio as 6.56, based on the Vmax and Km kinetics observed for
enalapril uptake and metabolism that were previously observed in homogenous isolated
rat hepatocyte studies (152-154).
As a greater amount of kinetic information about transporter and enzyme intrinsic
clearances, along with other physiological information, becomes available for different
drugs, the precision of more detailed physiologically-based models can continually
improve. Indeed, there has been continued development in dynamic models for intestinal
absorption and BBB permeability in recent years as well (155-158).
1.3.2.2 Facilitated (Carrier-mediated) transport kinetics
Carrier-mediated transport of substrate across a membrane is characterized by saturability
and it can be described analogously with the Michaelis-Menten equation for enzyme
kinetics,
v=

 ! "
# "

[1.6]

where v is the rate of carrier-mediated transport; Vmax is the maximum rate of carriermediated transport; C is the substrate concentration; and Km, is the Michaelis constant,
calculated as the substrate concentration at half of Vmax. When C is much smaller than
Km, the rate of transport, v, shows a linear proportionality with substrate concentration.
However, as C gets large compared to Km the rate of transport no longer increases in
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proportion to C, and v plateaus at a constant value (Vmax). At Vmax transport is saturated
and v is limited by the rate at which transporters turn over substrate and by the density of
transporters on the plasma membrane. To determine Vmax and Km in vitro, transport is
measured over a time course and over a range of drug concentrations. The Michaelis
constant is a substrate-dependent parameter that relates to the affinity of a given
transporter for a specific substrate.
The Michealis-Menten equation was originally developed for soluble enzymes, which
bind their substrates directly from the aqueous phase. Application of this equation to the
kinetics of transport assumes that the equation parameters correlate reasonably well with
the association and dissociation elementary rate constants of the substrate, transporter,
and substrate-transporter complex (159). This is a reasonable approximation for drug
transporters that bind their substrates directly from the aqueous phase and/or for the
ATPase activity that occurs in the aqueous phase for ABC transporters (160). Thus, while
the Michaelis-Menten parameters may not directly describe the discrete physical
processes of drug transport, they still offer a useful estimate of transporter activity and
good predictive value.
1.3.3 In vitro systems for estimating metabolism and transport
1.3.3.1 Hepatocytes, recombinant cells, and membrane vesicles
Drug metabolizing enzyme activity is estimated in vitro, often as an in vitro intrinsic
metabolic clearance using equation [1.7], by incubating a drug substrate in an appropriate
in vitro system and measuring metabolite formation or substrate disappearance over a
range of concentrations. Currently, isolated human hepatocytes in suspension are the
most practical in vitro system for metabolism studies to predict whole organ drug
clearance (161; 138; 162). Microsomal fractions and recombinant enzyme systems may
be used for more specific testing of particular enzymes of interest. Routine studies are
recommended by the FDA to characterize the interactions of compounds with the
following enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and
CYP3A (113).
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Freshly isolated cryopreserved hepatocytes can also be used to study hepatic uptake
transporters in vitro (162; 163). The common approach is to incubate substrate with a
suspension of hepatocytes and measure drug accumulation in the cell after a period of
time. Typically accumulation is measured over a range of concentrations to demonstrate
saturable active transport kinetics. These active transport studies yield Michaelis-Menten
kinetic parameters for carrier-mediated transport:
V=(

$%&  
$



 ( Pdiff × C)

[1.11]

Where V is the rate of carrier-mediated transport, Vmax is the maximum rate of carriermediated uptake, Km is the Michaelis constant, C is the drug concentration, and Pdiff is
the non-carrier-mediated passive clearance. Addition of the Pdiff × C product to the usual
Michaelis-Menten equation for active transport is necessary to account for the component
of in vitro transport rate into the cell that is due to passive, non-carrier-mediated
transport.
Application of Michaelis-Menten kinetics to in vitro carrier-mediated transport studies
often operates under the assumption that only one type of transporter is responsible for
transport in the system. Significant contribution by other transporters with overlapping
substrate specificity can obscure the activity of the transporter of interest and interfere
with the estimation of its kinetics. In the case of fresh hepatocytes, a variety of different
transporter families are in fact expressed that may contribute to transport of various drug
substrates. Also, cryopreserved hepatocytes cannot be used to study efflux transporters
because the process of hepatocyte isolation causes canalicular efflux transporters to be
internalized (164; 165). As well, none of the in vitro studies done in hepatocytes are
appropriate for the study of transporters that are not expressed in the liver, including
organic cation transporter 2 (OCT2) and organic anion transporter 1 and 3 (OAT1and 3)
proteins, which localize to the kidney. Recombinant cells can be used to better isolate the
activity of any individual uptake transporter on a drug of interest.
An important distinction must be made before attempting to apply the models described
above to the in vitro study of drug efflux transporters. Uptake transporters bind substrate
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from the extracellular environment, where measurement and manipulation of drug
concentrations is technically achieved very easily in a suspension or permeable-support
system. Efflux transporters, on the other hand, extrude substrate from the intracellular
space, which is largely inaccessible in these experimental systems. As such, more
sophisticated in vitro strategies must be employed in determining the kinetics of efflux
transport.
The ATPase, calcein-AM fluorescence, and rhodamine-123 fluorescence assays all
circumvent the issue of intracellular inaccessibility by using indirect measures of
substrate transport. The ATPase assay estimates the activity of ABC efflux transporters,
by measuring the ATP hydrolysis that is coupled to their transport activity. Calcein-AM
and rhodamine-123 fluorescence cell assays are designed specifically to evaluate ABCB1
(P-gp) or ABCC1 (Multidrug resistance-associated protein 1, MRP1) efflux transporter
activity. Non-flourescent calcein-AM or non-fluorescent rhodamine-123 diffuses into
cells where it is hydrolyzed by intracellular esterases into a fluorescent compound, which
accumulates intracellularly. Membrane P-gp and MRP1, however, opposes the inward
diffusion of these non-fluorescent compounds into the cells. Consequently, drugs that
interact with P-gp or MRP1 can affect efflux transporter activity, resulting in a
measureable change in the rate of accumulation of intracellular fluorescent compound.
(166; 167) Each of these indirect assays offers a high throughput analysis of potential
substrates that is readily automated. But, the ATPase, calcein-AM fluorescence, and
rhodamine-123 fluorescence assays are not able to distinguish efflux transporter
substrates from inhibitors (167-169).
Alternatively, other strategies allow direct measurement of efflux transporter activity; the
inverted membrane vesicle assay is one such strategy. Transporter-expressing plasma
membrane vesicles are inverted, such that the efflux transporters bind and actively pump
substrate from the external environment into the closed vesicle. This orientation permits
easy manipulation and measurement of the donor drug concentrations that is seen by the
efflux transporters. In this orientation transporter kinetics can be evaluated just as they
would be for an uptake transporter. However, compounds with moderate-to-high passive
permeability leak back out of the vesicle after being pumped in and thus may be falsely
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labeled as non-substrates by the inverted membrane vesicle assay. Moreover, the relative
orientation of efflux transporters, they being inside-out or outside-in facing, will impact
the effectiveness and interpretation of transport kinetics.
1.3.3.2 The cell monolayer permeability assay for efflux transport
The cell monolayer permeability assay is also designed to measure efflux transport
activity in a direct fashion and it is the gold standard used in industry (Figure 1.4). The
assay estimates efflux transporter activity by assessing permeability – comprised of both
passive diffusion and active transport – across a monolayer composed of an immortalized
cell line. The monolayer cells either have innate polarized efflux transporter expression,
or are transfected to stably or transiently express polarized recombinant efflux
transporter. A “transwell” set up is employed, where the monolayer is grown on a
semipermeable insert, which is set into a well. This set up creates one accessible
compartment on each side of the cell monolayer; commonly, as determined by cell
polarization in culture, the top compartment is apical and the bottom is basolateral. Then,
in order to estimate apical efflux transporter activity, which pumps drug away from the
basolateral compartment and towards the apical compartment, drug is added to either side
of the monolayer (the donor compartment) and its appearance on the opposing side (the
receiver compartment) is measured. Efflux transporter activity is reflected in the degree
of drug movement from donor to receiver compartments.
Like the inverted membrane vesicle assay, monolayer permeability assays may also fail
to identify the efflux transport of some highly permeable drugs, but carrier-mediated
efflux is unlikely to pose a significant barrier to the in vivo absorption of highly
permeable drugs. Another limitation of this model is its inability to directly measure
intracellular drug concentrations, which is the level that actually drives the rate of apical
efflux transporters. For convenience, the intracellular concentration is often assumed to
be in rapid equilibrium with the drug concentration measured in the basolateral
compartment, which can be easily manipulated. In this way the system can be viewed as
a single apical efflux barrier between two testable compartments: the
basolateral/intracellular compartment and the apical compartment. In reality however, the
intracellular concentration can vary significantly from the basolateral compartment
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Figure 1.3. The cell monolayer permeability assay. A polarized monolayer of cells with
apical P-gp expression. Papp is calculated in both directions from drug flux into the
receiver compartment following apical or basolateral administration.
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depending on the presence of unaccounted for basolateral uptake processes, which may
differ between the monolayer cell lines used and/or between laboratory culture conditions
(170-174). As previously mentioned, the presence of unaccounted for transporters can
obscure accurate determination of the activity and kinetics of a transporter of interest.
1.3.4 In vitro estimation of drug efflux activity in the monolayer permeability
assay
Various calculations have been proposed to estimate efflux transporter activity from a
cell monolayer permeability assay.
1.3.4.1 Directional apparent permeability
Since the presence of P-gp or other unidirectional apical efflux transporters can both
enhance basolateral to apical flux and attenuate apical to basolateral flux of a substrate
drug, efflux transporter activity can be assessed from the permeability in either direction.
Both increased basolateral to apical apparent permeability (Papp(B-A)) and decreased apical
to basolateral apparent permeability (Papp(A-B)) are used to identify a compound as a
substrate for efflux transport.
The apparent permeability (Papp) of a compound in one direction across the monolayer is
estimated from the rate of appearance of drug in the receiver compartment measured
during an incubation time. It is given by the following equation,
Papp = (dAR/dt)/(S×CD,0)

[1.12]

Where Papp is the apparent permeability in distance per unit time, dAR/dt is the cumulative
amount of compound appearing in the receiver compartment with respect to incubation
time, S is the surface area across which transport occurs, and CD,0 is the initial
concentration administered to the donor compartment. For Papp(B-A), dAR/dt specifies the
rate at which drug appears in the apical compartment and CD,0 is the initial concentration
added in the basolateral compartment. Oppositely, for Papp(A-B), dAR/dt specifies the rate
at which drug appears in the basolateral compartment and CD,0 is the donor concentration
added in the apical compartment.
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1.3.4.2 Efflux ratio
Efflux ratio (EfR), the ratio of Papp(B-A) to Papp(A-B), is also used to evaluate efflux
transporter activity. It relates the relative permeabilities in both directions across the
monolayer, demonstrated by the relationship in Equation 1.13,
EfR = Papp(B-A)/Papp(A-B)

[1.13]

Where EfR is the efflux ratio, Papp(B-A) is the basolateral to apical permeability of the drug
across the cell monolayer and Papp(A-B) is the apical to basolateral permeability. A drug
that does not experience any active efflux would have an EfR equal to 1. Conversely, a
substrate for apical efflux transport would show increased EfR (value > 1), demonstrating
asymmetric basolateral to apical permeability.
1.3.4.3 Modeled intrinsic transport clearance
Efflux transporter activity can also be estimated from a cell monolayer permeability assay
as a modeled intrinsic transporter clearance (CLint(Transport)). Cellular kinetic models of
varying complexity have been designed to describe drug movement between
compartments of a transwell system, with respect to time (171; 172; 176-178). The drug
concentrations, which are experimentally measured from the donor and receiver
compartments throughout the drug incubation period, can be used as inputs for
mathematical models to derive parameter values for the dynamic kinetic processes of the
transwell. The intrinsic efflux clearance (CLint(Efflux) or CLint), as it is defined in any given
model, provides a direct quantitative estimate of the activity of efflux transporters on an
in vitro test drug. This is different than Papp and EfR, which only qualitatively estimate
efflux transporter kinetics. Also unlike Papp and EfR, this modeled approach isolates and
quantifies the activity of the efflux transporter of interest. Take for example, the
compartmental model applied by Tam et al. (Figure 1.4); this model was able to examine
specifically the effect of P-gp efflux transport on drug metabolism in cytochrome P450
expressing Caco-2 cell intestinal models (173).
Since the modeled clearance approach isolates the activity of a given transporter, it
should also be more easily relatable across the various cell lines that are commonly used
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Figure 1.4. Compartment model for drug transport in a Transwell experimental system.
Permeation of drug (D) from the apical compartment into the cell compartment, whether
mediated by uptake transporters or passive diffusion, is associated with the absorption
rate constant, ka; secretion (efflux) from the cell back into the apical compartment occurs
with the intrinsic clearance, CLint,sec. Drug partitioning between the cell and the
basolateral compartment is mediated by influx and efflux clearances, CLd1 and CLd2,
respectively, as shown. Drug binding to proteins present in the apical compartment due to
sloughed off mucosal cells (unbound fraction fap), within the cell (unbound fraction fcell),
and in the basolateral compartment (unbound fraction fbaso) affects the transfer and
metabolic rates based on unbound drug concentrations. The rate of total metabolite
formed, under first-order conditions, is given by fcellDcellCLint,met/Vcell, where Dcell is the
amount of drug within the cellular compartment of volume, Vcell. Modified from Tam et
al., 2003.
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for monolayer permeability assays. Modeled clearance can account for uptake transport
parameters as well as other passive and active transport processes that may be specific to
different cell lines or culture conditions. In this way, modeled CLint should be
transfereable between systems, whereas Papp and EfR values derived from different
systems may not relate well. CLint is thus likely more useful for extrapolating the efflux
transport activity of a particular transporter in question.
1.3.5 Current recommendations for in vitro assessment of efflux transporter
activity
Some of the most important considerations for constructing a successful in vitro study
with good in vivo predictive value are: the selected test system, analysis of experimental
data, and the chosen test drug.
Of the available in vitro techniques, monolayer permeability assays are recommended for
in vitro assessment of efflux transporter activity (17; 179-183). More specifically,
colorectal adenocarcinoma (Caco-2) cells have been commonly used in industry and
academia for study of P-gp efflux transporter interaction and used as a general in vitro
model of intestinal absorption (184-187). Caco-2 cells are a continuous cell of
heterogeneous human epithelial colorectal adenocarcinoma cells, which shows high level
of endogenous P-gp expression on the apical membrane. In culture they take on
morphological and biochemical characteristics very similar to those of the human
intestinal epithelium, forming a confluent monolayer with tight junctions and a brush
border membrane. Data from Caco-2 cell assays has been shown to correlate well with
the in vivo absorption of orally administered drugs in man (188).
Notably, Caco-2 cells also show polarized expression of a variety of uptake and efflux
transporters. Many of these transporters share overlapping substrate specificities with Pgp and have the potential to contribute to the transport kinetics of P-gp subtrates. In
addition to P-glycoprotein, Caco-2 cells express significant levels of breast cancer
resistance protein (BCRP) and multidrug resistance-associated protein 2 (MRP2) efflux
transporters (189; 190) and fair levels of other transporters as well (Figure 1.5) (191195).
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Figure 1.5. Some of the putative transporter proteins expressed in cultured Caco-2 cells,
including: apical BCRP, MRP2, MDR1, HPT1 (human peptide transporter 1), PepT1
(peptide transporter 1), and OATP2B1 (organic anion-transporting polypeptide 2B1), and
basolateral MRP3, MRP1, and OST-α/β (organic solute transporter-α/β).
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Madin-Darby canine kidney (MDCK) cells and porcine kidney (LLCPK) cells can be
transfected with MDR1 and so are often used to form a polarized confluent monolayer in
vitro as an alternative to Caco-2 cells. The MDCK-MDR1 (MDCK cells stably
transfected with MDR1) and LMDR1 (LLCPK cells stably transfected with MDR1) cells
boast a shorter culture period and greater inter-passage homogeneity (182; 98). Also,
when transfected with MDR1 these cell lines typically overexpress P-gp at levels greater
than endogenous Caco-2 cell expression. Nonetheless, LLCPK and MDCK cells have
also been reported to show some native expression of other transporters and enzymes,
including fairly prominent canine P-gp expression in MDCK cells (196).
In terms of data analysis, some monolayer permeability studies report using
unidirectional apparent permeability for the evaluation of efflux transporter activity and
classification of P-gp substrates and modulators (197). However, efflux ratio is
commonly used in many other studies (179). Digoxin is also viewed as the ideal substrate
for the investigation of P-gp DDIs (113), and it will be discussed in detail in Section 1.4.
1.4

Digoxin
1.4.1 Historical perspectives

The cardiac glycosides are a group of chemically similar compounds that are often
referred to as digitalis or digitalis glycosides because most are derived from the digitalis
(foxglove) plant. The plant is native to western and south-western Europe, north-western
Africa, western and central Asia and Australasia. In 1785 physician William Withering
provided the first English language report of the use of cardiac glycoside-containing
digitalis extract in the treatment of heart conditions. Cardiac glycosides are now known to
inhibit the NA+/K+-ATPase pump in myocardial and smooth muscle cells. This creates an
increased intracellular sodium concentration, which induces elevated intracellular
calcium by means of the Na+/Ca2+ exchanger. The end result is increased contractility of
the heart through a positive inotropic effect. Typical cardiac glycosides function by the
same mechanism of action, but vary in their potency and pharmacokinetics.
The first digoxin product was brought to the American market in 1934 by Wellcome
Chemical Works (now GlaxoSmithKline) at a time when the FDA had limited power to
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regulate pharmaceuticals. As federal legislation evolved the FDA was empowered to
impose more stringent safety and efficacy tests on all pharmaceuticals, including those
already on the market. This resulted in several recalls of digoxin and eventually it’s
resubmission as a new drug. The secondary glycoside digoxin (Lanoxin) was ultimately
approved by the FDA in 1998 for heart failure, on the basis of the Digitalis Investigators
Group (DIG), Randomized Assessment of Digoxin on Inhibitors of the Angiotensin
Converting Enzyme (RADIANCE), and Prospective Randomized Study of Ventricular
Function and Efficacy of Digoxin (PROVED) clinical trials (198; 199; 200). Today
digoxin is the cardiac glycoside most commonly used in North America.
1.4.2 Indications and use in Canada
Current Heart Failure Society of America (AHA)/American College of Cardiology
(ACC) joint guidelines and Heart Failure Society of America (HSFA) guidelines
recommend digoxin use for the treatment of symptomatic chronic heart failure with
reduced or preserved systolic function and for ventricular rate control in atrial fibrillation
(201; 202). At present, digoxin is the only effective oral inotropic agent available for
treatment of chronic severe left systolic dysfunction (198; 203). Judicious use may also
be warranted in cases of renal hypokalemia, renal impairment, hypomagnesemia, and
hypothyroidism. When necessary, digoxin may also be carefully used in patients who
suffer acute myocardial infarction with ongoing ischemia or electrical cardioversion.
The therapeutic concentration of digoxin for most heart failure patients is between 0.5
and 1.0 ng/mL from a daily dose of 0.125 to 0.25 mg/day. Close drug monitoring is
especially imperative for digoxin because it has a very narrow therapeutic window, which
means that the concentration at which toxic effects appear (≥ 2 ng/mL) is not
substantially greater than therapeutic concentration. Early signs of digoxin toxicity are
central nervous systems effects including dizziness, visual disturbance and nausea. Major
digoxin toxicity is in large part a consequence of intracellular potassium depletion.
Digoxin is an affordable drug that, if properly monitored, can be used safely and
effectively in conjunction with other heart failure drugs. Importantly though, coadministration of digoxin with intravenous calcium can precipitate potentially fatal

39

arrhythmias. Digoxin should also be avoided in patients with sinus node disease, secondor third-degree atrioventricular block, accessory atrioventricular pathways, hypertrophic
cardiomyopathy, and cardiac amyloidosis. As well, physicians must be aware of the
potential for drug-drug interactions, particularly those mediated by P-glycoprotein.
1.4.3 Clinical pharmacology
Drug-drug interactions are a real concern because of their potential to push serum digoxin
concentrations outside of the narrow therapeutic window. Several clinically significant
DDIs involving digoxin have been previously reported (181). One of the most studied is
between digoxin and quinidine; first reported in 1968. Several prospective studies
independently confirmed the interaction, reporting 2- to 3-fold increase in digoxin
concentrations following concomitant quinidine administration (204; 205). This was
demonstrated to be a result of increased oral bioavailability by quinidine inhibition of
intestinal P-gp (206) and reduced renal clearance by inhibition of renal P-gp (207).
Likewise, concomitant administrations of cyclosporine, quinidine, amiodarone,
dronedarone, and valspodar with digoxin have all been reported to increase digoxin
plasma concentrations by competing for P-gp transport or protein binding (208-212).
Foods and other natural products have been shown to significantly affect digoxin
pharmacokinetics as well. For instance, several studies with St John’s Wort have
demonstrated decreased digoxin AUC resulting from induction of P-gp activity (213216).
1.4.4 Discovery as a P-gp substrate
Evidently, many digoxin DDIs are mediated by P-glycoprotein. The first in vitro
evidence for digoxin as a P-gp substrate came in 1992 from a study by de Lannoy and
Silverman in Canada and from a study in the same year by Tanigawara et al. in Japan.
Tanigawara’s group showed greater basolateral to apical transport of digoxin across an
epithelial monolayer of polarized LMDR1 cells. The directionality was diminished
significantly by the addition of the P-gp inhibitors vinblastine, quinidine, or verapamil.
Tanigawara’s group further demonstrated that while digoxin transport directionality is
reduced by cyclosporin inhibition of P-gp, digoxin did not reduce cyclosporin transport.
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In other words, digoxin is a substrate of P-gp, but not a modulator (218). Similar studies
conducted in different P-gp-expressing cells, including Caco-2 cells, and MDCK-MDR1
cells also identified digoxin as a P-gp substrate (219; 220; 98).
Additional in vivo work was done in knockout animal models. For example, Schinkel et
al. assessed digoxin disposition in mdr1a (-/-) mice (131). Following intravenous
injection they saw 35-fold greater digoxin accumulation in the brain of knockout mice
compared to wild type, demonstrating the efflux activity of blood-brain-barrier P-gp in
wild type mice. They also found that mdr1a (-/-) mice had 2-fold greater digoxin
exposure in the plasma and tissues overall, reflecting slower digoxin elimination in the
absence of active excretion by renal P-gp. In vitro work by Tsuruoka et al. further
supported the activity of mouse renal P-gp on digoxin (221). Finally, a study in IV-dosed
mdr1a (-/-) mice by Kawahara et al. also reported significant increase in digoxin AUC
and mean residence time, as well as reduced renal and biliary clearance in P-gp-knockout
mice (222).
At the turn of the century, human studies were underway to establish digoxin as a clinical
P-gp substrate. In 8 healthy volunteers, co-administration of rifampin significantly
reduced the AUC of orally dosed digoxin and, to a lesser extent, IV dosed digoxin (55).
This was attributed to rifampin induction of P-gp, which was directly measured from
duodenal biopsies. Decisive, in depth mechanistic clinical studies performed using
segmental intestinal perfusions demonstrated definitively that digoxin is indeed secreted
by the P-gp transporter (223; 224). A variety of similar studies with P-gp induction and
inhibition all confirmed convincingly that digoxin is a substrate of the human P-gp
transporter and that P-gp has a significant impact on digoxin disposition (225-229).
1.4.5 Digoxin pharmacokinetics
Digoxin is commonly administered as a commercially available tablet (Lanoxin), which
is taken orally. Peak serum concentrations (Cmax) are rapidly achieved 1 to 3 hours
following oral administration (230). The Cmax is somewhat delayed when taken with
food, but the total amount absorbed is generally unchanged, except in the case of a high
fiber meal. By the Biopharmaceutics Classification System (BCS), digoxin is a class II
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compound, with high permeability and low aqueous solubility (231). The bioavailability
of the oral dose is between 60 percent and 80 percent (232). However, patients with
malabsorption syndromes or with certain populations of colonic bacteria may see a
reduced digoxin oral bioavailability. Importantly, digoxin is also a substrate of the P-gp
efflux transporter, which can limit oral absorption at the apical membrane of enterocytes
(233).
The distribution phase of digoxin is between 6 and 8 hours, with a distribution half-life of
0.35 hours (234). The steady-state serum concentrations achieved after distribution are in
equilibrium with the digoxin concentrations in the tissues and thus these are the most
relevant serum concentrations for evaluating therapeutic and toxic effects. Digoxin has a
large Vd, showing substantial distribution into tissues (233). Very little digoxin moves
into adipose tissue however, and thus dosing should be based on lean body mass rather
than total body mass. Not surprisingly then, loss of muscle mass in elderly patients results
in a diminished Vd. Renal disease and hypothyroidism can also contribute to Vd
reduction. Digoxin has been shown to cross both the blood-brain-barrier and the bloodplacenta-barrier and is 25% serum protein bound (233).
Digoxin shows very little metabolism, only 13 percent. The primary metabolites are
dihydrodigoxin, digoxigenin and bisdigitoxoside and they are produced by non-CYP
enzymes. Renal excretion is the major route of digoxin elimination and between 50 and
70 percent of the parent compound is excreted unchanged in the urine (235). Given the
importance of the kidney in the elimination of digoxin, its half-life is prolonged in
patients suffering from renal failure. The typical half-life in patients with healthy renal
function though, is between 1.5 and 2 days (233).
1.4.6 Digoxin as a model P-gp substrate
Digoxin’s pharmacokinetics makes it an ideal in vitro probe substrate for the P-gp drug
transporter. According to the FDA 2006 draft guidance for drug interaction studies, an
in vitro P-gp probe substrate should be: selective to the P-gp transporter, have low
passive membrane permeability, show minimal metabolism, be commercially available,
and be safe for in vivo studies (17). Additional requirements applicable to human studies

42

should include a drug that is: safe and well tolerated by healthy subjects, approved for
human administration, rapidly absorbed with a short half-life to avoid long clinical
studies, minimally plasma protein bound, and quantifiable from plasma and/or urine
and/or fecal samples using validated analytical methods (236). Digoxin is a P-gp
substrate drug that is commercially available, both as cold- and radiolabelled- drug and it
adequately fulfills the aforementioned probe substrate criteria. It remains the
recommended probe drug for P-gp interaction studies according to the FDA and is
viewed as the gold standard for industry testing (17; 181; 183; 237; 238).
Though used less frequently than digoxin, fexofenadine – a histamine H1-receptor
antagonist used for the treatment of seasonal allergic rhinitis – is also an effective P-gp
probe drug. It is a demonstrated P-gp substrate: showing directional transport in Caco-2
cells that is suppressed by P-gp inhibitors, as well as significantly increased plasma and
tissue levels in MDR1 knockout mice (239-241). It shows minimal metabolism, with 95%
of a dose excreted unchanged in the urine and feces (242). Moreover, the 60 mg single
oral dose that is commonly used for in vivo studies is safe and tolerable and results in
accurate and detectable plasma concentrations (243; 244). Notably though, while
fexofenadine is commercially available, it is not available as an intravenous formulation.
As a result, fexofenadine has limited in vivo usefulness in distinguishing the activity of
intestinal versus renal P-gp. As well, commercially available fexofenadine is a racemic
mixture, which may introduce chiral-associated differences in the drug’s
pharmacokinetics that are independent of P-gp (245). Moreover, fexofenadine is reported
to be a substrate for several other transporters, many of which are expressed in cells
commonly used for permeability assay, including organic anion-transporting polypeptide
2B1 (OATP2B1) and multidrug resistance-associated protein 2 and 3 (MRP2 and MRP3).
These competing transporters can complicate interpretation of P-gp transport kinetics
(246).
1.5

Rationale

It is well appreciated that the activity of membrane transporter proteins plays an
important role in drug disposition, a critical determinant of the pharmacological and
toxicological profile of all drugs (247; 12). Like drug metabolizing enzymes, drug
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transporters are known to mediate significant drug-drug interactions as well as contribute
to population variation in pharmacokinetics. P-glycoprotein (P-gp) is a key clinically
important and well-characterized efflux transporter, which affects drug absorption,
distribution and elimination (112; 12; 114; 115). A great number of clinically relevant,
pharmacologically and structurally unrelated drugs are substrates for P-gp. Consequently,
the efflux transport activity of P-gp on various drugs and drug candidates is routinely
tested using the gold standard in vitro permeability assay across a monolayer of
polarized, P-gp expressing Caco-2, LMDR1, or MDCK-MDR1 cells. Different metrics –
namely apparent permeability Papp and efflux ratio EfR – are employed to evaluate P-gp
transporter activity in this assay, in order to identify P-gp substrates or modulators and to
extrapolate to in vivo and clinical pharmacokinetics. However, comparative assessment of
how well these metrics can specifically characterize the efflux transport activity of P-gp
is limited in the literature. In one study investigating the sources of inter-lab variability in
Caco-2 cell intestinal model predictions, Hayeshi et al. reported on the correlation
between varied P-gp mRNA expression levels in Caco-2 monolayers and the
corresponding P-gp activity estimates calculated by Papp and by EfR (248). Taipalensuu et
al. also reported on the correlation between efflux ratio and P-gp protein expression in
Caco-2 monolayers (249). But, there are no studies that evaluate the efficacy of Papp or
EfR to estimate P-gp activity across the various commonly used monolayer cell types.
Our study compares traditional metrics of P-gp activity in Caco-2, LLCPK and LMDR1
monolayer permeability assays, against a mechanistically-based compartmental modeling
approach, which generates a clearance CLP-gp to quantitatively describe the intrinsic
efflux activity of the P-gp transporter. We believe that a modeled clearance approach is a
superior metric for the permeability assay because it does not rely on the potentially
erroneous assumption that intracellular concentration is equal to basolateral
concentration. Rather, the modeled approach specifically and quantitatively estimates Pgp activity from a fitted intracellular concentration. At the same time, it accounts for
uptake transport parameters as well as other passive and active transport processes that
may be specific to the different cell lines that are used for monolayer permeability assays.
In this way, modeled CLP-gp should be transferable between different monolayer cell
types (e.g. Caco-2, LLCPK, and LMDR1) and in vivo, whereas Papp and EfR values
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derived from different systems may not interrelate well. Compared to the qualitative P-gp
transporter activity assessments offered by Papp and EfR, modeled CLP-gp is likely more
useful for the precise quantitative evaluation of the activity of the P-gp transporter in cell
monolayer permeability assays and ultimately more useful for quantitative in vitro to in
vivo extrapolation. To compare the merit of our model against the standard metrics, we
conducted monolayer permeability assays across Caco-2, LLCPK, and LMDR1 cell
monolayers that had a range of P-gp expression level and we employed unidirectional
permeability, efflux ratio, and modeled clearance metrics to estimate P-gp activity in each
assay. We then performed a statistical analysis to compare all metrics for overall validity
and sensitivity across cell systems.
1.6

Objectives
1.

To establish multiple cell monolayer permeability in vitro systems with
different levels of P-gp expression/activity.

2.

To evaluate P-gp efflux activity in the different cell systems using the
traditional metrics and a modeled intrinsic P-gp clearance.

3.

To compare the validity and sensitivity of the different metrics of efflux
transporter activity across cell systems.

1.7

Hypothesis

We hypothesize that modeled clearance (CLint(Transport)) is a more valid and sensitive
measure of P-gp activity in the in vitro cell monolayer permeability assay than Papp and
EfR.
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Chapter 2
QUANTITATIVE ESTIMATION OF P-GLYCOPROTEINMEDIATED DRUG TRANSPORT IN THE MONOLAYER
PERMEABILITY ASSAY BY MECHANISTICALLY
MODELED INTRINSIC CLEARANCE
2.1 Introduction
Interindividual differences in drug response and toxicity continue to be a challenge to
optimal drug therapy (1). It is well appreciated that differences in drug action among
patients relate to variability in the levels of drug in the blood. Cell membrane-bound
transporter proteins play an important role in drug absorption, distribution, and excretion
pharmacokinetic processes, which are critical determinants of drug levels and hence the
pharmacological and/or toxicological profile of all drugs and xenobiotics (2; 3). Many
common polymorphisms in drug transporters have been linked to altered drug
pharmacokinetics and transporters are also the basis of many clinically relevant drugdrug interactions (DDIs) (3). Whole cell and expression system in vitro assays of drug
metabolizing enzyme activities yield kinetic information that is essential for in vitro to in
vivo extrapolation (IVIVE) of drug levels and for mechanistic understanding and
prediction of DDIs and pharmacokinetics in the clinical setting (4; 5). Interestingly
though, such biochemical characterization of drug transporter activity today remains
inadequate, despite the important role of transporters in drug pharmacokinetics (5).
P-glycoprotein (P-gp), encoded by the Multidrug Resistance 1 (MDR1, ABCB1) gene, is
the most clinically important and well-characterized efflux transporter, responsible for
pumping drugs from inside cells to the outside milieu. P-gp is widely expressed on the
apical membrane in tissues such as liver, kidney, intestines, and at the blood-brainbarrier, indicating its important role in drug disposition. A large number of
pharmacologically and structurally unrelated drugs are substrates for P-gp, including:
anti-cancer agents, steroid hormones, antimicrobial agents, opioids, immunosuppressants,
antiarrhythmics, antihistamines, cholesterol-lowering statins, and HIV protease
inhibitors, to name a few (6).
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Given the clinical relevance of P-gp, an initial in vitro assay of P-gp transporter activity is
typically performed for a drug in order to predict P-gp-drug interaction and guide further
in vivo studies. Convention has been to measure drug flux across a tight monolayer of
apical-basolateral polarized cells that have apical P-gp expression (7; 8). The apparent
permeability (Papp) of a drug across the monolayer is estimated from the appearance of
drug in the receiver compartment over time [Equation 1.12]. Due to polarized expression
of P-gp efflux transporter on the apical membrane, a P-gp substrate drug would be
expected to show increased Papp in the basolateral-apical direction (Papp(B-A)) and
decreased Papp in the apical-basolateral direction (Papp(A-B)). The ratio of Papp(B-A)/Papp(A-B),
known as the efflux ratio (EfR) [Equation 1.13], is then said to estimate P-gp transport
activity on a substrate drug; the assumption being that EfR and Papp(B-A) are proportional
to P-gp activity and Papp(A-B) is inversely proportional to P-gp activity (8).
Papp = (dAR/dt)/(S×CD,0)

[1.12]

EfR = Papp(B-A) /Papp(A-B)

[1.13]

While EfR, Papp(B-A), and Papp(A-B) can effectively identify most P-gp substrates, specific
estimation of P-gp activity may be limited. Apparent permeabilities and efflux ratios,
which are measured directly from flux across the monolayer, view the system as a single
barrier with drug actively transported directly from the donor compartment to the receiver
compartment. In reality it is the intracellular drug concentration, not the donor
compartment concentration that interacts with P-gp on the apical membrane. Therefore,
EfR, Papp(B-A), and Papp(A-B) do not account for the potentially rate limiting active uptake
processes on the basolateral or apical membranes that move drug from the donor
compartment into the intracellular compartment, where drug-P-gp interaction occurs.
Consequently, EfR, Papp(B-A), and Papp(A-B) metrics fail to specifically characterize P-gp
transport and thus may not show direct proportionality with P-gp transporter activity and
expression (9; 10).
We propose utilizing a mathematical model that incorporates all potentially rate limiting
active and passive transport processes occurring at both the apical and basolateral
membranes (Figure 2.1). By fitting flux data to this model, we can estimate the kinetics
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of P-gp transport from the intracellular space. The output parameter from this exercise
CLP-gp, P-gp intrinsic clearance, is then a mechanistically-based quantitative estimate of
P-gp transporter activity. In order to compare this modeled approach for P-gp activity
estimation with the typical metrics, we conducted several monolayer permeability assays
with a range of P-gp expression and appraised the correlation of Papp, EfR, and CLP-gp
with P-gp expression in each assay. In theory, the level of P-gp expression on the apical
membrane of polarized cells should be directly proportional to measured P-gp transport
activity when the transporter is not saturated. We hypothesize that the modeled clearance
(CLP-gp) is a superior metric of P-gp activity compared to Papp or EfR.

71

Figure 2.1. Schematic presentation of the compartmental model, with apical (A),
basolateral (B), and cell (C) compartments represented. CL parameters define the transit
efficiencies between compartments of volume V and drug concentration C.
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2.2
2.2.1

Materials and Methods
Materials

Human colorectal adenocarcinoma [Caco-2] and porcine kidney epithelial [LLCPK] cells
were obtained from American Type Culture Collection ATCC (Manassas, VA). LLCPK
cells overexpressing MDR1 [LMDR1] were a generous gift from Dr. A.H. Schinkel (The
Netherlands Cancer Institute, Amsterdam, Holland) and Dr. E. Schuetz (St. Jude
Children’s Research Hospital, Memphis, TN). Dulbecco’s modified Eagle’s medium
(DMEM), fetal bovine serum (FBS), penicillin-streptomycin, nonessential amino acids
(NEAA) and 0.05% trypsin-EDTA were all purchased from Life Technologies (Grand
Island, NY). Vincristine sulfate with a purity exceeding 97.5 [HPLC], 1α,25dihydroxyvitamin D3 with purity exceeding 99% [HPLC], thiazolyl blue tetrazolium
bromide (MTT) with purity exceeding 98% [HPLC], digoxin with purity exceeding
96.4% [HPLC], and protease inhibitor were all sourced from Sigma-Aldrich (St. Louis,
MO). Transwell cell culture inserts (12-well, 0.4 um) were purchased from VWRInternational (Mississauga, ON). [3H]-Digoxin (specific activity, 21.8 Ci/mmol), was
obtained from PerkinElmer Life & Analytical Sciences (Boston, MA). [14C]-Inulin
(specific activity, 8.5mCi/mmol), with purity exceeding 95% [HPLC] was from Moravek
Biochemicals (Brea, CA). Ultima Gold scinitillation cocktail was purchased from
PerkinElmer (Waltham, MA). Thermo Scientific Pierce IP lysis buffer and Thermo
Scientific Restore Western Blot Stripping Buffer were obtained from Fischer Scientific
(Ottawa, ON). Western Blocking Reagent was purchased from Roche (Indianapolis, IN).
C219 monoclonal p-glycoprotein antibody was purchased from Covance (Dedham, MA).
Polyclonal goat anti-actin antibody (C-11) was obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Goat anti-mouse IgG (H + L)-HRP conjugate was purchased from
BioRad Canada (Mississauga, ON). Amersham ECL select western blotting detection
reagent was purchased from GE Healthcare UK (Little Chalfont, Buckinghamshire).
2.2.2

Cell Culture

Caco-2 (passage no. 20-35), LLCPK (passage no. 5-15), and LMDR1 (passage no. 5-15)
cells were cultured in DMEM supplemented with 50 ug/ml streptomycin, 50 U/mL
penicillin and 10% fetal bovine serum. LMDR1 culture media was also supplemented

73

with 10% NEAA and 640 nM vincristine to maintain P-glycoprotein expression. Cells
were incubated at 37°C in 5% CO2 in a humidified environment.
2.2.3

MTT Assay

MTT assay was performed on Caco-2 cells in 96-well plates with approximately 1.2×104
cells per well. Cells were treated in triplicate with 0 nM to 1500 nM 1α,25(OH)2D3 every
other day for 14 days. On day 15 cells were washed with phosphate-buffered saline
(PBS) and 25 µL of 5 mg/mL MTT in PBS was added to each well. The plates were
incubated for 4 h at 37 °C and the formazan formed was dissolved in 50 µL of dimethyl
sulfoxide (DMSO). The background absorbance at 670 nm was subtracted from the
absorbance at 569 nm to obtain the raw absorbance data (Thermo Multiskan
spectrophotometer).
2.2.4

Digoxin Flux Studies

Cells were seeded in 12-well plates at a density of 90,000 cells per 0.4-µm cell culture
insert and grown for 14 days with media changes every 2 days. Each time the media was
changed, Caco-2 cells were treated with 0 nM (Caco-2 (0nM)), 10 nM (Caco-2 (10 nM)),
or 100 nM (Caco-2 (100 nM)) of the P-gp inducer 1α,25(OH)2D3 dissolved in DMSO.
Approximately 1 h before the start of a transport experiment, the media was removed
from each compartment (apical and basal) and washed and replaced with pH 7.4 KrebsHenseleit Bicarbonate Buffer (KHB). Transport was initiated by removing the KHB and
replacing it with 700 µl of KHB with or without 5 uM digoxin (3.5 µmol of digoxin) +
5.7 nM [3H]-digoxin to the appropriate compartment in triplicate. [14C]-Inulin was
included in each plate in triplicate as a marker of paracellular flux. The cells were
incubated at 37°C with 5% CO2 in a humidified environment, and 25-µl aliquots were
removed hourly from each compartment over 4 h. Each aliquot was mixed with 5 mL of
Ultima Gold scintillation cocktail and counted using a PerkinElmer TriCarb2900 TR
liquid scintillation counter.
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2.2.5

Estimation of P-gp Activity

2.2.5.1 Conventional Estimates: Papp(A-B), Papp(B-A), and EfR
Apparent permeability (Papp) in both directions was determined as follows:
Papp = (dAR/dt)/(S×CD,0) [cm/s]

[1.12]

where dAR/dt is the rate of drug ([3H]-digoxin or [14C]-inulin) appearance in the receiver
compartment, S is the surface area of the cell culture insert , and CD,0 is the initial
concentration added to the donor compartment. This model is derived from Fick’s first
law of diffusion, assuming a constant linear concentration gradient across a single barrier
and a sink condition. Efflux ratio (EfR) was determined as follows:
EfR = Papp(B-A)/Papp(A-B)

[1.13]

where Papp(B-A) is the apparent permeability in the basolateral to apical direction and
Papp(A-B) is the apparent permeability in the apical to basolateral direction.
2.2.5.2 Mathematical Modeling of Transport Intrinsic clearance: CLP-gp
The three-compartment kinetic model (Figure 2.1) uses a set of mass balance differential
equations [Equations 2.1-2.3] to describe digoxin flux in a transwell as a one-dimensional
process between an apical, a cellular, and a basolateral kinetic compartment. The
volumes used for the apical, cell, and basolateral compartments were fixed at 700 µL,
2.76 µL and 700 µL respectively, and drug dispersion within the compartments was
viewed as rapid and even.The cell volume was estimated using a previously reported
geometric approach of multiplying cell heights by the surface area of cell culture inserts
(9). CLP-gp describes the efflux clearance at the apical membrane that is mediated by Pgp. CLA-C and CLC-B describe the net clearance due to all other transcellular transport
processes (excluding P-gplycoprotein-mediated clearance) across the apical membrane
and the basolateral membrane respectively; we assumed symmetrical transcellular
clearance at both membranes. Rate equations describing the model (Figure 2.1) were
solved numerically using the Episode (Adams) integrator (Scientist, Micromath, Salt
Lake City, Utah). The P-gp clearance parameter (CLP-gp ) and both net basolateral and
apical clearance parameters (CLA-C and CLC-B ) were estimated by simultaneous least
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squares fitting of [3H]-digoxin flux data for drug administration in both directions to the
model. Fitting of the paracellular clearance parameter (CLA-B) was done separately using
simultaneous fitting of bidirectional [14C]-inulin flux data, with all other clearance
parameters set to zero. All fitted parameters were constrained to be positive numbers. The
differential equations that describe the model are as follows:
In the apical compartment
VAdCA/dt = -CACLA-C + CCCLA-C – CACLA-B + CBCLA-B + CCCLP-gp

[2.1]

In the cellular compartment
VCdCC/dt = -CCCLA-C + CACLA-C – CCCLC-B + CBCLC-B – CCCLP-gp

[2.2]

In the basolateral compartment
VBdCB/dt = -CBCLC-B + CCCLC-B – CBCLA-B + CACLA-B

[2.3]

Where dCA/dt, dCC/dt and dCB/dt is the rate of change of drug concentration in the apical,
cell and basolateral compartments respectively; VA, VC and VB are the volumes in each
compartment; and CA, CC and CB are the drug concentrations. Where CLA-B represents
the paracellular clearance; CLA-C and CLC-B represent the non-P-gp transcellular
clearance across the apical and basolateral membranes respectively; and CLP-gp represents
the P-glycoprotein-mediated apical efflux clearance.
2.2.6

Immunoblotting and P-gp Quantitation

At the end of each transport experiment, the cells were collected from cell culture insert
membranes, washed with ice cold PBS and then lysed in lysis buffer containing protease
inhibitor by the Thermo Scientific IP lysis buffer protocol. The whole-cell lysates were
then stored at -80 °C for future analysis by western blot. Control Caco-2 cells were
grown in a 10 cm plate, lysed with the Thermo Scientific IP lysis buffer protocol and the
whole cell lysate was loaded on every western blot. Protein concentrations of all lysates
were determined by Pierce BCA protein assay (Fisher Scientific, Whitby, ON). Forty µg
of control Caco-2, 20 µg of LLCPK, Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2 (100
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nM) and 5 µg of LMDR1 whole cell lysate protein was separated on a NuPAGE 4-12%
Bis-Tris gel (Invitrogen, Carlsbad, CA). Detection of P-glycoprotein expression was
performed by overnight incubation with anti-P-glycoprotein antibody (C219), diluted
1:500 in PBS with 0.1% Tween 20 and 10% western blocking reagent. To confirm equal
loading of lysates, the blot was stripped and incubated with a polyclonal goat anti-actin
antibody, at a dilution of 1:20,000 (C-11; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). Actin expression could not be assumed to be constant between LLCPK and Caco-2
cell types, thus normalizing to actin was not performed. Horseradish peroxidase-linked
anti-mouse or anti-goat antibodies (Biorad) were used as the secondary antibodies. Blots
were visualized using Amersham ECL Western blotting system (GE) and a Kodak
ImageStation 4000 MM (Eastman Kodak Company, Rochester, New York). Protein
expression was quantified by densitometry with ImageJ. All samples were quantified
relative to the control Caco-2 whole cell lysate loaded on each blot. All quantified
densitometry values were multiplied by a loading correction factor, to account for the
different amounts of protein loaded between cell types.
2.2.7

Comparison of P-gp Transport Activity Metrics

For each transwell experiment, the derived CLP-gp value was plot against the measured Pgp expression. CLP-gp values vs. protein expression data set generated from the 5 different
transwell experiment types (Caco-2 (0 nM), Caco-2 (10 nM), Caco-2 (100 nM), LLCPK,
and LMDR1) was then fit by linear regression using Prism 5.0 (GraphPad Software Inc,
San Diego, CA). The same process was repeated for Papp(A-B), Papp(B-A) and EfR estimates
of P-gp activity respectively. The lines of best fit were then compared for goodness of fit
(r2) and slope.
2.2.8

Statistical Analysis

Statistical differences between group parameters were determined by 1-way ANOVA or
2-way ANOVA, using Boneferroni’s multiple comparison test as appropriate (GraphPad
Software Inc, San Diego, CA). A P value of <0.05 was considered statistically
significant.
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2.3

Results

2.3.1

Cell Monolayer Viability

The [14C]-inulin permeability values for the cell monolayers used in the transport
experiments are displayed in Table 2.1. Evidently, Vitamin D treatment (10 nM or 100
nM) did not significantly alter [14C]-inulin permeability across Caco-2 cell monolayers.
All Caco-2 cell conditions showed significantly higher [14C]-inulin permeability than
LLCPK and LMDR1 monolayers. But, all five monolayer conditions demonstrated
acceptable membrane integrity, with inulin permeabilities ≤ 5×10-6 cm/s.
Viability of Caco-2 cells treated with various concentrations of 1,25(OH)2D3 for 14 days
was assessed by MTT assay (Figure 2.2). Concentrations as high as 500 nM 1,25(OH)2D3
were tolerable by Caco-2 cells, with only a 15% rate of cytotoxicity. This concentration
was fivefold higher than the concentration used in our high vitamin D treatment
condition.
2.3.2

Transport Experiments

[3H]-Digoxin transport across the LLCPK and LMDR1 cell monolayers is shown in
Figure 2.3. For [3H]-digoxin movement out of the donor compartment (Figure 2.3A)
there was a trend towards greater flux in the basolateral to apical (B-A) direction in the
LMDR1 cells as compared to LLCPK. As well, flux in the apical to basolateral (A-B)
direction was significantly smaller in the LMDR1 cells. In the receiver compartment
(Figure 2.3B) flux in both directions was significantly different between the two cell
types. The LMDR1 cells had comparatively greater B-A flux and less A-B flux than the
LLCPK cells. Overall, the disparity in B-A versus A-B flux was significantly greater in
the LMDR1 cells.
[3H]-Digoxin transport across Caco-2 cells treated with 0 nM, 10 nM and 100 nM
1,25(OH)2D3 is shown in Figure 2.4. From the donor compartment (Figure 2.4A) A-B
flux in the Caco-2 cells treated with 100 nM 1,25(OH)2D3 was significantly decreased
compared to the Caco-2 cells not treated with 1,25(OH)2D3. Basolateral to apical flux
however, did not significantly differ between the treatment groups. In the receiver
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Table 0.1. Apparent permeability coefficients and net efflux ratio of bidirectional [14C]inulin transport over a 4 hour time course, across the various cell monolayers.
Monolayer Cell
Type
LLCPK
LMDR1
Caco-2 (0 nM)
Caco-2 (10 nM)
Caco-2 (100 nM)
a,b

Papp(A-B) (×10-6 cm/s)

Papp(B-A) (×10-6 cm/s)

EfR

3.122 ± 0.134

2.989 ± 0.153a

0.948 ± 0.014

3.886 ± 0.585

a

0.867 ± 0.079

4.430 ± 0.359

b

0.953 ± 0.034

4.067 ± 0.285

b

0.982 ± 0.002

4.121 ± 0.275

b

1.026 ± 0.024

4.557 ± 0.277
4.142 ± 0.291
4.056 ± 0.299

2.481 ± 0.175

p < 0.05 compared between monolayer cell types

Caco-2 cells were treated every other day with culture media only (Caco-2 (0 nM)), or
with culture media + 10 nM (Caco-2 (10 nM)) or + 100 nM (Caco-2 (100 nM))
1,23(OH)2D3 for 2 weeks. Data are presented as mean ± S.E. (n=6).
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Figure 2.2. The cytotoxic effect of vitamin D (1,25(OH)2D3) on cultured Caco-2 cells.
Caco-2 cells (passage 15-35) were treated with various concentrations of vitamin D every
other day for 14 days and cell survival was assessed by MTT assay. Data are expressed as
the percentage of viability compared to control non-treated cells performed in the same
experiment. Data are presented as mean ± S.D. (n = 1 experiment, 3 technical replicates).
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Figure 2.3. Cumulative amounts of [3H]-digoxin transported from the donor
compartment (A) and into the receiver compartment (B) of the LLCPK and LMDR1 cell
monolayer, for the A-B and B-A direction, over a 4 hour time course. The transport study
was performed on day 15. Data are presented as mean ± S.E. (n=4-6).
*, p < 0.05 between A-B - LLCPK and A-B - LMDR1; †, p < 0.001 between B-A LLCPK and B-A - LMDR1.
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Figure 2.4. Cumulative amounts of [3H]-digoxin transported from the donor
compartment (A) and into the receiver compartment (B) of the Caco-2 cell monolayer,
for the A-B and B-A direction, over a 4 hour time course. Prior to transport, Caco-2 cells
were treated every other day with culture media only (●/▼), or with culture media + 10
nM (■/♦) or + 100 nM (▲/○) 1,25(OH)2D3 for 2 weeks. The transport study was
performed on day 15. Data are presented as mean ± S.E. (n≥4).
*, p <0.05 between A-B - Caco-2 (0 nM) and A-B - Caco-2 (100 nM); †, p < 0.05 B-A Caco-2 (10 nM) and B-A - Caco-2 (100 nM).
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compartment (Figure 2.4B) A-B flux was significantly lower and B-A flux was
significantly higher in the Caco-2 (100 nM) cells as compared to the Caco-2 (0 nM) cells.
B-A flux was also significantly smaller in the Caco-2 (10 nM) cells as compared to the
Caco-2 (100 nM) cells. Evidently, the disparity in B-A versus A-B flux was significantly
larger in Caco-2 cells treated with 100 nM 1,25(OH)2D3 versus Caco-2 cells treated 0 nM
or 10 nM 1,25(OH)2D3.
2.3.3

P-gp Protein Expression

Figure 2.5 shows C219 antibody western blots of the whole cell lysates collected from
the various transwell cell monolayers after each transport experiment; the 170 kDa P-gp
protein was expressed in all cell types in a range increasing from LLCPK < Caco-2 (0
nM) < Caco-2 (10 nM) < Caco-2 (100 nM) < LMDR1. Table 2.2 shows the densitometry
quantification of the P-gp western blots, corrected for the different sample amounts
loaded. P-gp expression was generally consistent across experiment days; the standard
deviation for P-gp expression within a cell type was between 5 and 10 percent. On
average LLCPK cells showed 25 fold less P-gp expression than the LMDR1 cells stably
transfected with the MDR1 gene. Caco-2 cells showed about two fold more expression
than LLCPK cells, but treatment with 10 nM and 100 nM 1,25(OH)2D3 induced
approximately a 2-fold and 3-fold increase in Caco-2 cell P-gp expression, respectively.
2.3.4

Permeability and Efflux Ratios

We generated the apparent permeability values of digoxin across the different
monolayers from flux data (Figure 2.6). Comparing bidirectional permeability between
the LLCPK and the LMDR1 cell monolayers (Figure 2.6A), B-A permeability was
significantly higher than A-B permeability in both cell types, but A-B permeability was
significantly depressed, by 12 fold, in the LMDR1 cells versus the LLCPK cells. P-gp
expression in the LMDR1 cells did not produce a significant increase in the B-A
permeability of digoxin above that seen in the LLCPK cells. In examination of
bidirectional permeability in the Caco-2 cells that were treated with various
concentrations of 1,25(OH)2D3 (Figure 2.6B), B-A permeability was again significantly
higher than A-B permeability in all cell monolayers. Caco-2 cells treated with 10 nM and
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Figure 2.5. Western blots, using a mouse monoclonal anti-P-gp antibody (C219) (I) and
a polyclonal goat anti-actin antibody (C-11) (II), of transwell monolayer cell lysates from
experiment Day 1 (A), Day 2 and 3 (B), Day 4 (C), Day 5 (D), and Day 6 (E). , The
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monolayer lysates in (A), (C), (D), and (E) were loaded as LLCPK [Lane 1], LMDR1
[Lane 2], Caco-2 (0 nM) [Lane 3], Caco-2 (10 nM) [Lane 4] and Caco-2 (100 nM) [Lane
5]; in (B) they were loaded as LLCPK (Day 2) [Lane 1], LMDR1 (Day 2) [Lane 2],
Caco-2 (0 nM) (Day 2) [Lane 3], and LLCPK (Day 3) [Lane 4]. The same control Caco-2
cell lysate was loaded for densitometry comparison on every blot [Lane 0]. 40 µg of
protein was loaded for all Caco-2 control lysates; 5 µg of protein was loaded for all
LMDR1 monolayer lysates; 20 µg was loaded for all other monolayer lysates.
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Table 0.2. Relative P-gp and Actin protein expression in transwell monolayer cells
collected from each experiment day, as compared to the control Caco-2 cell lysate.

*Cells from transwell experiments with leaky monolayers ([14C]-inulin permeability > 5 × 10-6 cm/s) were excluded from
the study
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100 nM 1,25(OH)2D3 showed respectively 2 fold and 2.7 fold less A-B permeability than
untreated Caco-2 cells, but did not show significantly different A-B permeability
compared to each other. Conversely, in the B-A direction Caco-2 cells treated with 10
nM 1,25(OH)2D3 did show significantly less permeability than 100 nM treated cells, by
1.3 fold, but 10 nM treated cells did not show significantly different B-A permeability
compared to untreated Caco-2 cells. Comparing all cell monolayers in the A-B direction
(Figure 2.6C), digoxin permeability was significantly higher in LLCPK cells than all
other cell conditions. A-B permeability was significantly diminished by 2.8 fold in
LMDR1 cells compared to untreated Caco-2 cells, but not significantly so when
compared to Caco-2 cells treated with 1,25(OH)2D3. For all monolayers in the B-A
direction (Figure 2.6D), 100 nM 1,25(OH)2D3 treated Caco-2 cells showed significantly
higher B-A permeability, but a significant difference was not seen between the B-A
permeabilities of any of the other conditions. There was a slight trend though towards
decreased B-A permeability in the LLCPK cells.
Efflux ratios generated from the flux data are presented in Figure 2.7. LLCPK monolayer
showed an EfR close to 1, which was significantly smaller than the LMDR1 monolayer
by 5.4 fold and smaller than the three Caco-2 monolayer conditions by 2 fold, 3.7 fold,
and 6.9 fold respectively. There was a significant trend towards increasing EfR values in
response to increasing 1,25(OH)2D3 concentration. Untreated Caco-2 cells had the lowest
EfR, Caco-2 cells treated with 10 nM 1,25(OH)2D3 were 1.7 fold higher than untreated.
The EfR of Caco-2 (100 nM) cells was 2.6 fold higher than untreated Caco-2 cells and
was not significantly different from the LMDR1 cell monolayer EfR.
2.3.5

Modeled Clearance

Generation of the CLP-gp values required fitting of the transport data to our kinetic
compartmental model [Equations 2.1-2.3], which encompasses parameters for
paracellular clearance between an apical and basolateral compartment, as well as
parameters for clearance at separate apical and basolateral barriers. An average digoxin

87

Figure 2.6. Apparent permeability coefficients for the transport of [3H]-digoxin, over a 4
hour time course, in the A-B and B-A direction across LLCPK and LMDR1 cell
monolayers (A), in the A-B and B-A direction across Caco-2 (0 nM), Caco-2 (10 nM)
and Caco-2 (100 nM) cell monolayers (B), in the A-B direction across LLCPK, LMDR1,
Caco-2 (0 nM), Caco-2 (10 nM) and Caco-2 (100 nM) cell monolayers (C), and in the BA direction across LLCPK, LMDR1, Caco-2 (0 nM), Caco-2 (10 nM) and Caco-2 (100
nM) cell monolayers (D). Caco-2 cells were treated every other day with culture media
only [Caco-2 (0 nM)], or with culture media + 10 nM [Caco-2 (10 nM)] or + 100 nM
[Caco-2 (100 nM)] 1,25(OH)2D3 for 2 weeks. Data are presented as mean ± S.E. (n=4-6).
Permeabilities with a different superscript letter (a, b, c, or d) are significantly different;
p<0.05.
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Figure 2.7. Efflux ratio of bidirectional [3H]-digoxin transport for 4 hours across the
different cell monolayers. Data are presented as mean ± S.E. (n ≥ 4). EfRs with a
different superscript (a, b, c, or d) are significantly different; p<0.05.
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paracellular clearance parameter, CLA-B, was estimated for each transwell cell type from
fit of average [14C]-inulin transwell flux data to the same compartmental model. Using
these fitted CLA-B values, the model was able to simulate the average [14C]-inulin
transport data very well for all cell types (Figure 2.8). Fixing these CLA-B values as the
paracellular clearance parameters in our digoxin compartmental model, we then fit the
models to the average digoxin transport data for each cell type in order to generate
average transcellular clearance parameters CLA-C, CLC-B, and CLP-gp. Model simulation
using these fitted CLA-C, CLC-B, and CLP-gp parameter values also matched the average
digoxin transport data quite well for all cell types (Figures 2.9 and 2.10).
As was seen with EfR, modeled P-gp clearance (CLP-gp) values increased from LLCPK <
Caco-2 (0 nM) < Caco-2 (10 nM) < Caco-2 (100 nM) < LMDR1 (Figure 2.11A). CLP-gp
in LMDR1 cells was 14.3 fold greater than in LLCPK cells, but we only see a small nonsignificant 1.5 fold difference between modeled CLP-gp for LLCPK and Caco-2 (0 nM)
cells. Similar values of CLP-gp are seen between Caco-2 (0 nM) and Caco-2 (10 nM).
Treatment with 100 nM of vitamin D yielded a significantly greater CLP-gp, 3.0 fold
higher than untreated Caco-2 cells.
In agreement with the [14C]-inulin permeability data (Table 2.1), the modeled values for
paracellular clearance, CLA-B, were fairly consistent across all cell types, but higher in the
3 different Caco-2 cell groups (Figure 2.11D). In contrast, the modeled non-P-gp
transcellular clearance was not uniform across cell types; CLA-C and CLC-B parameters
were very similar between LLCPK and LMDR1 cells, but in Caco-2 (0 nM) cells CLA-C
and CLC-B was around 4 fold and 2 fold greater respectively (Figure 2.11B and C).
Evidently, treatment with vitamin D in the Caco-2 (10 nM) and Caco-2 (100 nM) groups
reduced the CLA-C and CLC-B down to levels similar to that seen in LLCPK and LMDR1
cells.
Estimates of P-gp activity made by compartmental modelling as well as the estimates
made by traditional permeability and efflux ratio methods for all transport experiments
are summarized in Tables 2.3 and 2.4.
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Figure 2.8. Model fits of inulin transport across LLCPK (A), LMDR1 (B), Caco-2 (0
nM) (C), Caco-2 (10 nM) (D), and Caco-2 (100 nM) (E) monolayers, using Equations
2.1-2.3, with a CLA-B parameter value fit from average [14C]-inulin transport data. Solid
lines and broken lines represent simulations of the apical dosed and basolateral dosed
inulin transport respectively. ■ and▲ represent apical and basolateral dosed inulin data
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points respectively. Data points presented are the average of 6 transport experiments ±
SE.
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Figure 2.9. Model fits of digoxin transwell transport across LLCPK (A) and LMDR1
(B) cell monolayers out of the donor compartment (I) and into the receiver compartment
(II), using Equations 2.1-2.3, with CLP-gp, CLA-C, and CLC-B parameter values fit from
average [3H]-digoxin transport data. The solid line and the broken line represent model
fits of the apical dosed and basolateral dosed digoxin transport respectively. ■ and▲
represent apical and basolateral dosed digoxin data points respectively. Data points
presented are the average of 6 transport experiment days ± SE.
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Figure 2.10. Model fits of digoxin transwell transport across Caco-2 (0 nM) (A), Caco-2
(10 nM) (B), and Caco-2 (100 nM) (C) cell monolayers out of the donor compartment
(I) and into the receiver compartment (II), using Equations 2.1-2.3, with CLP-gp, CLA-C,
and CLC-B parameter values fit from average [3H]-digoxin transport data. The solid line
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and the broken line represent model fits of the apical dosed and basolateral dosed digoxin
transport respectively. ■ and▲ represent apical and basolateral dosed digoxin data points
respectively. Data points presented are the average of 6 transport experiment days ± SE.
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Figure 2.11. Modeled CLP-gp (A), CLA-C (B), CLC-B (C), and CLA-B (D) of bidirectional
[3H]-digoxin transport for 4 hours across the different cell monolayers. Data are
presented as mean ± S.E. (n ≥ 4). CL values with a different superscript (a, b, or c) are
significantly different; p<0.05.
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Table 0.3. Estimates of P-gp activity in LLCPK and LMDR1 cell monolayers for each
experiment day, evaluated by traditional apparent permeability (Papp(A-B), Papp(B-A)) and
efflux ratio (EfR) approaches, as well as by P-gp intrinsic clearance (CLP-gp) fit from our
3-compartment model. Modeled clearance values for non-P-gp transcellular flux (CLA-C,
CLC-B) and paracellular flux (CLA-B) are also included for each experiment.
Day

Traditional Estimates
Papp(A-B)
Papp(B-A)
EfR
×10-6 cm/s

×10-6 cm/s

LLCPK
1
2
3
4
5
6

1.807
3.045
1.147
1.470
1.442
1.910

2.742
4.587
2.052
2.776
2.650
3.015

Avg
SD

1.804
0.272

2.970
0.349

1.578
1.686
0.070

LMDR1
1
2
3
4
5

0.316
0.448
0.352
0.341
0.333

2.952
3.340
3.418
3.087
3.226

9.351
7.458
9.710
9.053
9.683

Avg
SD

0.358
0.023

3.2046
0.084

9.051
0.416

CLP-gp
×10-6 L/hr

1.518
1.506
1.789
1.889
1.838

Modeled Clearance
CLA-C
CLC-B

CLA-B

×10-6 L/hr

×10-6 L/hr

×10-5 L/hr

27.124
32.592
19.318
24.339
41.390
9.447
25.704
4.482

5.317
6.010
6.262
4.974
1.900
8.446
5.485
0.715

8.309
10.739
6.294
3.840
13.825
5.888
8.149
1.484

11.439
15.821
12.486
15.431
17.663
10.019
13.810
1.201

244.017
279.562
400.468
493.313
420.310
367.473
46.182

1.045
1.342
6.369
8.835
3.945
4.307
1.489

10.262
5.256
12.949
13.320
8.666
10.091
1.484

7.151
10.527
13.466
18.203
28.913
15.652
3.779
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Table 0.4. Estimates of P-gp activity in Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2
(100 nM) cell monolayers for each experiment day, evaluated by traditional apparent
permeability (Papp(A-B), Papp(B-A)) and efflux ratio (EfR) approaches, as well as by P-gp
intrinsic clearance (CLP-gp) fit from our 3-compartment model. Modeled clearance values
for non-P-gp transcellular flux (CLA-C, CLC-B) and paracellular flux (CLA-B) are also
included for each experiment.
Day

Traditional Estimates
Papp(A-B)
Papp(B-A)
EfR
×10-6 cm/s

×10-6 cm/s

×10-6 L/hr

Caco-2 (0 nM)
1
1.234
2
0.806
3
1.485
4
0.626
5
0.799

2.939
3.353
3.304
3.148
3.110

2.383
4.158
2.224
5.031
3.891

Avg
SD

0.990
0.159

3.171
0.074

3.537
0.538

Caco-2 (10 nM)
1
0.275
2
0.905
3
0.379
4
0.46

1.662
4.113
2.997
3.038

6.039
4.547
7.839
6.599

Avg
SD

0.505
0.139

2.953
0.502

6.256
0.683

Caco-2 (100 nM)
1
0.182
2
0.539
3
0.36
4
0.385

3.442
4.247
3.761
3.661

18.912
7.877
10.46
9.517

Avg
SD

3.778
0.170

11.692
2.465

0.367
0.073

CLP-gp

Modeled Clearance
CLA-C
CLC-B

CLA-B

×10-6 L/hr

×10-6 L/hr

×10-6 L/hr

38.64
29.70
36.71
31.95
38.98
35.20
1.86

1.055
3.918
5.861
9.045
1.324
4.240
1.491

40.80
20.16
9.76
23.89
14.64
21.85
5.31

19.16
10.83
43.52
28.35
10.83
22.54
6.16

50.23
57.98
47.66
55.60
52.87
2.37

1.485
2.451
1.069
1.074
1.520
0.325

2.39
18.74
13.62
18.86
13.40
3.87

9.84
17.44
26.29
29.53
20.78
4.45

95.63
94.53
83.22
148.59
105.49
29.27

1.068
1.011
0.951
1.945
1.244
0.210

22.67
6.51
24.01
12.66
11.36
4.22

8.40
15.22
28.09
28.81
20.14
4.48
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2.3.6

Predictive performance and sensitivity of P-gp activity metrics

Figures 2.12-2.15 show a linear regression of normalized P-gp activity versus normalized
P-gp expression for each metric; Table 2.5 summarizes the outcomes of linear regression
analyses. The r2 value for the linear regression of CLP-gp activity estimates was over three
fold greater and the slope was over six fold greater than the Papp(A-B) and EfR activity
estimates. Papp(A-B) and EfR estimates of P-gp activity did both fit a linear regression with
P-gp expression, with p-values < 0.05. The difference between modeled clearance and the
traditional P-gp activity metrics was far less striking when we focused our analysis on
only the subset of data within one cell type (Table 2.5(A) and (B)). Indeed, when we
isolated Caco-2 cell expression and flux data for analysis, the r2 values for the linear
regressions of EfR and Papp(A-B) activity estimates was less than 2 fold smaller than CLP-gp
and the slope was actually greater for the EfR linear regression compared to CLP-gp.
When we excluded the Caco-2 cell data the r2 value for the EfR linear regression was
greater than CLP-gp and Papp(A-B) was only slightly smaller than CLP-gp. The slope (m) of
the CLP-gp regression was however, substantially larger than EfR and Papp(A-B) by 4.7 fold
and 6.8 fold respectively. CLP-gp and EfR linear regressions consistently showed greater r2
and slope compared to Papp(A-B). Papp(B-A) estimates of P-gp activity did not fit a linear
regression with P-gp expression in any analysis; the p-value was well above 0.05 for all
subsets of data analyzed (Table 2.5).
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Figure 2.12. Normalized P-gp protein expression in various transwell monolayer cell
types versus the corresponding normalized P-gp transport activity estimates obtained by
Papp(A-B) calculation method. P-gp expression was quantified by western blot
densitometry relative to a control Caco-2 cell lysate that was loaded on each blot. Protein
expression and activity estimates were normalized respectively to the averaged
expression and the averaged estimated activity of the Caco-2 (0 nM) transwell monolayer
cells. Slope (m) and goodness of fit (r2) are presented for the linear regression of all data
sets combined (A), only LLCPK and LMDR1 data sets combined (B), and only Caco-2
(0 nM), Caco-2 (10 nM), and Caco-2 (100 nM) data sets combined (C). The p-value of
the F-test for a non-zero slope is also presented for each linear regression.
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Figure 2.13. Normalized P-gp protein expression in various transwell monolayer cell
types versus the corresponding normalized P-gp transport activity estimates obtained by
Papp(B-A) calculation method. P-gp expression was quantified by western blot
densitometry relative to a control Caco-2 cell lysate that was loaded on each blot. Protein
expression and activity estimates were normalized respectively to the averaged
expression and the averaged estimated activity of the Caco-2 (0 nM) transwell monolayer
cells. Slope (m) and goodness of fit (r2) are presented for the linear regression of all data
sets combined (A), only LLCPK and LMDR1 data sets combined (B), and only Caco-2
(0 nM), Caco-2 (10 nM), and Caco-2 (100 nM) data sets combined (C). The p-value of
the F-test for a non-zero slope is also presented for each linear regression.
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Figure 2.14. Normalized P-gp protein expression in various transwell monolayer cell
types versus the corresponding normalized P-gp transport activity estimates obtained by
EfR calculation method. P-gp expression was quantified by western blot densitometry
relative to a control Caco-2 cell lysate that was loaded on each blot. Protein expression
and activity estimates were normalized respectively to the averaged expression and the
averaged estimated activity of the Caco-2 (0 nM) transwell monolayer cells. Slope (m)
and goodness of fit (r2) are presented for the linear regression of all data sets combined
(A), only LLCPK and LMDR1 data sets combined (B), and only Caco-2 (0 nM), Caco2 (10 nM), and Caco-2 (100 nM) data sets combined (C). The p-value of the F-test for a
non-zero slope is also presented for each linear regression.
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Figure 2.15. Normalized P-gp protein expression in various transwell monolayer cell
types versus the corresponding normalized P-gp transport activity estimates obtained by
CLP-gp calculation method. P-gp expression was quantified by western blot densitometry
relative to a control Caco-2 cell lysate that was loaded on each blot. Protein expression
and activity estimates were normalized respectively to the averaged expression and the
averaged estimated activity of the Caco-2 (0 nM) transwell monolayer cells. Slope (m)
and goodness of fit (r2) are presented for the linear regression of all data sets combined
(A), only LLCPK and LMDR1 data sets combined (B), and only Caco-2 (0 nM), Caco2 (10 nM), and Caco-2 (100 nM) data sets combined (C). The p-value of the F-test for a
non-zero slope is also presented for each linear regression.
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Table 0.5. Summary of goodness of fit (r2) and regression slopes (m) for regression
analyses of different normalized estimates of P-gp activity with P-gp expression for
LLCPK and LMDR1 data sets only (A), Caco-2 (0 nM), (10 nM), and (100 nM) data
sets only (B), and all data sets combined (C).
Papp(A-B)

Papp(B-A)

EfR

ClP-gp

(A) LLCPK and LMDR1 data sets only

r2
slope

0.7022
0.03421
0.9784
-0.1091 ± 0.0237
0.0053 ± 0.0094
0.1576 ± 0.0078
(B) Caco-2: 0 nM, 10 nM, and 100 nM data sets only

r2
slope

0.4512
-0.2689 ± 0.0894
(C) All data sets

r2
slope

0.2576
-0.0749 ± 0.0271

0.9102
0.7465 ± 0.0782

0.1434
0.0789 ± 0.0581

0.6131
1.005 ± 0.2407

0.7930
0.8942 ± 0.1377

0.005123
0.0030 ± 0.0089

0.2730
0.1300 ± 0.0452

0.9222
0.8086 ± 0.0501
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2.4

Discussion

The objective of this study was to compare the validity and sensitivity of a modeled
intrinsic clearance against unidirectional apparent permeability and efflux ratio as metrics
of P-gp activity across monolayer permeability assay systems. We hypothesized that
since modeled clearance measures P-gp activity more directly and specifically, it is
superior to apparent permeability and efflux ratio for evaluating P-gp activity in any
monolayer permeability assay.
We found that the validity and sensitivity of modeled clearance as a P-gp activity metric
is generally on par with efflux ratio and superior to unidirectional apparent permeability
for assays conducted in monolayers of a common cell type. But, when making P-gp
activity estimates across different cell types, modeled clearance is far superior to the
traditional metrics. Indeed, when we separated assays by cell type (Caco-2 (0 nM)/Caco2 (10 nM)/Caco-2 (100 nM) or LLCPK/LMDR1), the correlation of CLP-gp-estimated
monolayer P-gp activity vs. measured monolayer P-gp expression had similar or greater
slope (sensitivity) and r2 value as compared to the correlations of Papp-estimated P-gp
activity vs. P-gp expression and EfR-estimated P-gp activity vs. P-gp expression; but the
r2 and slope were respectively 3.4-fold and 6.2-fold greater for CLP-gp when we evaluated
the combined data from both cell types together.
Caco-2, LMDR1, and MDCK-MDR1 cells are all commonly used for cell monolayer
permeability assays (11-14). Some level of polarized apical P-gp expression has been
demonstrated in each of these cell types, such that they can all be used to demonstrate
substrates or modulators of P-gp activity in vitro. Previous reports though, found that
relative P-gp expression differs between Caco-2, MDCK-MDR1 (not included in our
study), LLCPK, and LMDR1 cell types (15; 16), which agreed with the western blot
findings in our study. Our blots also agreed with previous studies that have reported a
concentration-dependent increase in P-gp expression in Caco-2 cells treated with vitamin
D (17; 18). Some models of intestinal absorption and metabolism rely on vitamin D
treatment to induce CYP3A4 activity in Caco-2 monolayers. So, LLCPK, LMDR1 and
Caco-2 cells and Caco-2 cells treated with vitamin D are all commonly utilized in cellbased models and assays of permeability; and because of their inherent differences in P-
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gp expression, our study had a suitable range of cell monolayer P-gp expression across
which to examine the validity and sensitivity of P-gp activity metrics.
The level of P-gp expression in a given monolayer cell system dictates the level of P-gp
efflux activity. Accordingly, from cursory assessment of our transport data there is
evidence of increaing efflux transport – marked by increasing basolateral to apical
disparity in bidirectional flux – in the rank orders LLCPK<LMDR1 and Caco-2 (0 nM) <
Caco-2 (10 nM) < Caco-2 (100 nM), which paralleled the rank orders of cell monolayer
P-gp expression. In our study though, the basolateral to apical apparent permeability did
not demonstrate this relationship with cell monolayer P-gp expression. We found no
correlation between Papp(B-A) and P-gp expression in Caco-2 cells, in LLCPK/LMDR1
cells, or in Caco-2 and LLCPK/LMDR1 cells. This result conflicted with previous studies
by Taipalensuu et al. and Hayeshi et al., who reported correlation between Caco-2 cell Pgp expression and both basolateral to apical apparent permeability and efflux ratio (14;
19). Possible explanation for our conflicting results could relate to plastic adsorption in
the basolateral compartment or cellular retention of drug passing through the cell from
the basolateral compartment into the apical compartment. Youdim et al., suggests that
traditional permeability equations fail to account for cellular retention (20). The loss of
drug to cellular retention and plastic adsorption during transport experiments could
certainly lead to false measurements of a drug’s permeability value (20-22). Our model
exercise does suggest though that lack of correlation between Papp(B-A) with P-gp
expression is most likely due to the fact that digoxin permeability at the basolateral
membrane is significantly lower than efflux activity at the apical membrane. This
indicates that overall basolateral to apical digoxin transcellular flux is rate-limited by
basolateral membrane permeation rather than P-gp activity. However, the Papp(A-B) and
EfR values calculated in our experiments did show a correlation with P-gp expression in
Caco-2 cells, which agreed with previous studies (14; 19). Similarly in LLCPK/LMDR1
cells we also saw correlation between Papp(A-B) and P-gp expression and between EfR and
LLCPK/LMDR1 cells.
In explaining why CLP-gp reflects P-gp activity more predictably and sensitively when
comparing between cell types, we believe this relates not to difference in P-gp expression
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between cell types, but to differences in non-P-gp transporters and cell morphology that
also contribute to drug transit. Aside from P-gp, Caco-2 cells, LMDR1 cells, and MDCKMDR1 cells have all been reported to show different relative expression levels of several
transporters, including but not limited to:, MRP2, and BCRP apical efflux transporters,
peptide transporter 1 (PepT1) apical uptake transporter, multidrug resistance-associated
protein 3 (MRP3), MRP1, and organic solute transporter-α and -β (OST-α and -β)
basolateral efflux transporters and OATP-A (SLC21A3), OATP-C (SLC21A6), and
OATP-B (SLC21A9) basolateral uptake transporters (23-30; 19). Many of these
transporters have overlapping substrate specificities with P-gp and thus multiple
transporters may contribute, to varying degrees in different monolayers, to the flux of any
given drug that is being tested for specific interaction with P-gp. As Sun and Pang
demonstrated in a theoretical study, the presence of other active transport has the
potential to overcome the effect of P-gp apical efflux activity, which could result in the
over- or under-estimation of traditional monolayer permeability metrics of P-gp activity
(9). This may even apply to the prototypical P-gp probe substrate, digoxin. Some non-Pgp transporters have been previously implicated in digoxin transcellular flux across assay
monolayers. Sun and Pang’s theoretical study predicted the kinetic presence of a
basolateral digoxin uptake transporter in Caco-2 cells and there has been evidence in
MDCK cells of active basolateral uptake of digoxin that is inhibited by GF120918 (9;
31). There have also been reports that digoxin is transported by OST-α and -β (32), which
is expressed in Caco-2 cells. There is a clear potential for other transporters to obscure
the monolayer permeability that Papp and EfR attribute solely to P-gp activity. Yet, though
many transporters may contribute to flux across Caco-2, LLCPK or MDCK monolayers,
we are not aware of any comprehensive studies in the literature that directly compare
transporter expression patterns between these cells. Difficulty assessing differences in
transporter expression among these cells lines will be compounded by species-related
differences in transporter activity towards specific substrates. Consequently, it is difficult
even to anticipate the relative impact of different transporters on monolayer transit
between cell lines; so, it is hard to know how much Papp or EfR measured in a given cell
type may be over- or under-estimating P-gp activity.
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While the non-P-gp transporter differences are overlooked in the calculation of EfR and
Papp as estimates of P-gp activity, in our modeled clearance the general effects of non-Pgp transporter difference are imbedded within the fitted CLA-C and CLC-B parameters. The
difference that we observed between the CLA-C and CLC-B parameters fitted from Caco-2
data versus LLCPK/LMDR1 data seem to reflect the reported difference in non-P-gp
transport activity between Caco-2 and LLCPK/LMDR1 cells.
Although transporter differences between cell lines may not have been compared in great
detail, certain morphological differences between Caco-2, LLCPK, and MDCK cells
have been documented. Caco-2 cells, for example, are well known to form in vitro
monolayers with greater integrity and lower transepithelial electrical resistance (TEER)
than MDCK cells (33). In their theoretical study, Sun and Pang demonstrated the
potential for paracellular flux to obscure apical efflux (9). Since paracellular transit
differs between cell types, as was also demonstrated in our study by measurement of the
paracellular marker [14C]-inulin, the degree to which paracellular flux obscures the Papp
and EfR estimations of P-gp also differs between cell types. For our model CLP-gp
however, the difference between Caco-2 and LLCPK/LMDR1 paracellular [3H]-digoxin
transit is imbedded in the CLA-B parameter. Therefore, the CLP-gp estimate of P-gp
activity derived from any monolayer assay is, theoretically, independent of the integrity
characteristics of a particular monolayer.
Transporter and morphological differences between cell types, or even within a cell type,
can be further complicated by differences in laboratory practice. Owing to the intrinsic
heterogeneity of the parental Caco-2, LLCPK and MDCK cell lines, culture-related
conditions have been shown to influence the morphological and functional characteristics
of in vitro monolayers, by selecting for sub populations of cells in culture (34).
Variability has been previously reported in Caco-2 cell paracellular permeability and
transporter expression (35; 36) and has been ascribed to difference in culture conditions,
passage number and cell source (37-39; 19). This results in significant variability in the
estimates of P-gp activity calculated by Papp or EfR, even in the same in vitro system and
cell type (40). In effect, the value of the monolayer permeability assay for assessing P-gp
activity and IVIVE becomes limited when we use Papp or EfR for any moderate substrate
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of P-gp that has broad transporter specificity or high passive permeability. By specifically
isolating the activity of P-gp transporter from the other active and passive transport
processes in a monolayer permeability assay, CLP-gp is able to effectively extract more
widely useable data for any laboratory working with their preferred assay conditions.
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Chapter 3
General Discussion
3.1

Study Objective

The objective of this study was to compare the validity and sensitivity of unidirectional
apparent permeability and efflux ratio against modeled intrinsic clearance, as metrics of
P-gp activity in the monolayer permeability assay. Our rationale was that Papp and EfR
only provide a qualitative estimate of P-gp activity from general drug flux across an assay
monolayer, whereas CLP-gp quantitatively estimates specific P-gp-mediated efflux from
the cell compartment at the apical membrane. Therefore, the mechanistically based
estimate would be expected to be more sensitive and valid across cell systems and
variable laboratory assay conditions. Moreover, CLP-gp provides quantitative values that
can be directly applied for IVIVE, unlike Papp and EfR. No prior studies have compared
these P-gp activity metrics across different commonly used assay cell systems. Here, our
main objective was to obtain experimental data to prove that modeled clearance estimates
P-gp activity better than Papp and EfR across monolayer permeability assay cell types.
3.2

Monolayer permeability assay metrics of P-gp activity

We compared the P-gp activity metrics across various cell types because, although Caco2, LLCPK and MDCK cells can all form an in vitro monolayer with polarized P-gp
expression, in vitro monolayers composed of these cell types differ in ways that
fundamentally affect the transit of test drugs. Our experiment cells differed in P-gp
expression in the rank order LLCPK < Caco-2 (0 nM) < Caco-2 (10 nM) < Caco-2 (100
nM) < LMDR1, and since, in theory, P-gp transport activity is directly proportional to Pgp expression, valid and useful transport activity metrics could be evaluated using data
from all experimental groups. It would appear that Papp(A-B), EfR and CLP-gp are all valid
metrics of P-gp activity when estimates are made within a common cell type (eg. in
Caco-2 (0 nM)/Caco-2 (10 nM)/Caco-2 (100 nM) or LLCPK/LMDR1); we found good
correlation between monolayer P-gp expression and respectively Papp(A-B), EfR, and CLPgp

estimates of monolayer P-gp activity. However, unidirectional apparent permeability

and efflux ratio are not good metrics when estimating monolayer P-gp activity across
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different cell types; poor correlation was shown between monolayer P-gp expression and
respective Papp and EfR estimates of P-gp activity. Unidirectional apparent permeability
and efflux ratio simplify transit across the monolayer as movement across a single barrier
driven only by P-gp transport (1-4). Our investigation suggests that this approximation
was adequate when estimating different P-gp activities within one cell type because the
action of the P-gp transporter alone was responsible for much of the difference seen in
[3H]-digoxin bidirectional flux between Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2
(100 nM) cell monolayers and between LLCPK and LMDR1 monolayers. But, difference
in isolated P-gp transport activity across a single barrier was not sufficient on its own to
account for the difference seen in [3H]-digoxin flux between LLCPK, Caco-2 (0 nM),
Caco-2 (10 nM), Caco-2 (100 nM), and LMDR1 monolayers. We conclude neither Papp
nor EfR are valid metrics of P-gp activity when comparing across cell types.
Conversely, we found our modeled CLP-gp is well suited to estimate P-gp activity within
and across cell types; with good correlation for all linear regression analyses. Our
compartmental model includes CLC-B and CLA-C to account for both passive and active
transport processes occurring in both directions across the basolateral and apical
membranes respectively. Thus, these parameters are able to account for non-P-gp
transporters on either membrane, which may contribute significantly to differences in
monolayer transit observed between monolayer cell types because Caco-2, LLCPK and
MDCK cells all show different transporter expression in vitro (1; 5-12). The model fitted
CLC-B and CLA-C parameters reflected the difference in non-P-gp transporter expression
between LLCPK/LMDR1 and Caco-2 cell types. Our model also includes CLA-B to
account for variable paracellular transit, which results from differences in monolayer
integrity that have been well documented between monolayer cell types (13; 14). By
accounting for all of these confounding processes, CLP-gp is able to tease out the specific
contribution of P-gp-mediated transport across all assays. In our investigation, modeled
clearance has proven to be a valid metric of P-gp activity between monolayer
permeability assay cell types.
Another ideal property of a quantitative metric for P-gp activity is sensitivity to varying
levels of P-gp expression and function. The relative sensitivity of metrics can be
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evaluated by comparing the slopes (m) of the relationships between normalized P-gp
activity and P-gp expression either within a cell type or with combined cell types. When
considering results from combined Caco-2 and LLCPK cells, the rank order of slope
values are Papp(B-A) < Papp(A-B) < EfR < CLP-gp. This indicates that across cell systems, CLPgp

is the most sensitive P-gp activity metric. However, within the LLCPK/LMDR1

system, slope values suggest that EfR is the most sensitive P-gp activity metric. CLP-gp
was the most sensitive measure of P-gp activity when evaluating data within the Caco-2
system.
3.3

Standardizing monolayer permeability assays

Given the importance of P-gp in the absorption, distribution, and excretion of drugs, it is
essential to have in vitro assays that are capable of assessing potential P-gp interactions.
A variety of biological systems are available to assess the potential for these interactions,
including ATPase assays, fluorescent assays, and membrane vesicles. But, monolayer
permeability assays are recommended as the most direct measure of P-gp activity (1520). For this reason, academic, industry, and regulatory laboratories regularly conduct
monolayer permeability assays on drugs to test for P-gp interaction using the standard
transwell set-up. But, there is great potential for individual laboratories to introduce
variability into this assay, which can make it challenging to draw congruent
pharmacokinetic conclusions from the same assay conducted in different laboratories.
First, as previously mentioned there is not one standard cell type used to compose the
monolayer; Caco-2, LLCPK, or MDCK are all commonly interchanged. Although each
of these cell types will spontaneously differentiate in vitro to form a monolayer with
polarized apical P-gp expression (21-24), we have clearly demonstrated in our study the
inherent challenge of trying to draw compatible conclusions about P-gp activity from
multiple monolayer cell types.
Moreover, owing to the inherent heterogeneity of the parent Caco-2, LLCPK, and MDCK
cell lines, lack of standardization in laboratory practice can amplify variability in the
permeability assay systems applied by different groups, regardless of chosen cell type.
There is significant inter-lab variability in culture conditions, transwell equipment, cell
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sources, cell passage number, seeding density, and bioanalytical techniques (25-28; 12).
Many labs gauge monolayer integrity by measuring TEER, while others use mannitol,
inulin, or Lucifer yellow flux. Furthermore, the monolayer integrity acceptance criteria
vary substantially even for labs using the same measure. Some laboratories conduct
transport experiments on a shaker, while others do not. The components of the culture
media and assay buffers may vary between labs as well. Many labs also have their own
protocol for seeding density and culture time of monolayer cells. Even plate and well
insert sources vary, as well as insert pore size. A comparative study looking at inter-lab
variability across 23 research laboratories and academic institutions found that 80% of
variability in P-gp IC50 estimates was due to the use of different laboratory practices
(28).
Consistency in the conclusions drawn about P-gp activity from monolayer permeability
assays, performed under such diverse conditions, necessitates either strict standardization
of assay protocols or a method of interpreting assay data that accounts for as much of the
assay variability as possible. Sambuy et al. performed an interlaboratory study of
mannitol permeability and TEER in Caco-2 cells with the goal of establishing a
standardized protocol that would allow meaningful comparison of results obtained in
different laboratories (29). We are not aware of any similar initiatives and none that
address variability in non-P-gp transporter expression, which contributes to substrate
transcellular flux variation. In this study though, we have explicitly demonstrated the
capability of modeled clearance to yield a standard P-gp activity output, at very least, for
the monolayer permeability assay variability that results from using different cell types.
In principle, this model should extend to standardize P-gp activity estimation for a variety
of different sources of assay variability.
3.4

Applying monolayer permeability assay data to drug discovery and
development

The output of monolayer permeability assays are meant to provide information about
whether a drug is a substrate of P-gp or the potential for P-gp mediated DDIs. Particularly
in the DDD process, monolayer permeability assays provide important preclinical
information in the early stages of drug candidate investigation that decides subsequent in
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vivo and clinical testing (15; 30-38). At these early stages though, the major role of
monolayer permeability assay is just to provide a qualitative yes or no assessment of
whether or not a drug is a substrate or inhibitor of P-gp. If yes, then more in-depth study
is conducted on the PK effects and potential DDIs. For this qualitative assessment,
standardization of assay cell types or conditions may not be crucial. Papp or EfR results
may show some variation between labs, but in practice, a compound with a measured EfR
of 10 in one lab that has a measured EfR of 12 in another lab will be assessed as a P-gp
substrate in either case. An issue arises however, for drugs that show only moderate
interaction with P-gp. For these drugs, close consensus would be required between Papp or
EfR estimates of P-gp activity made in different labs in order for the drug-P-gp
interaction to be harmoniously defined across laboratories. There have been reports of
drugs that appear as P-gp substrate in a Caco-2 assay, but not in a MDCK-MDR1 assay
(39). The consequence of a false negative or a false positive can be respectively, a failure
to conduct appropriate follow-up tests to collect critical PK information, or performing
needless subsequent studies that do not yield significant in vivo or clinical relevance.
CLP-gp is very important for its ability to bring consensus to the interpretation of P-gp
interactions made using monolayer permeability assays in different laboratories.
3.5

Applying monolayer permeability assay data to IVIVE

Although the use of monolayer permeability assays recommended by regulatory agencies
in the early stages of DDD focuses more on simple identification of P-gp substrates and
inhibitors, there is substantial interest in industry and academia in more detailed
characterization of P-gp interactions because of its important role in absorption,
distribution and excretion pharmacokinetics (30; 40; 41). Therefore, monolayer
permeability assays are also used as an important tool in in vitro to in vivo extrapolation
(IVIVE).
A drug that is identified as a substantial P-gp substrate by Papp or EfR, with an EfR of 20
for example, will then qualitatively be expected to show reduced clinical oral absorption
because of broad P-gp expression in the intestines. In order to make any quantitative
prediction from the monolayer permeability assay though, data must be properly
interpreted to characterize the P-gp activity in a physiologically relevant way.
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CLP-gp not only serves as a consensus metric of P-gp activity in monolayer permeability
assays, but it provides a quantitative and physiologically relevant assessment of P-gp
activity that can be applied directly to quantitative IVIVE. It is particularly useful for
quantitative IVIVE because it specifically characterizes P-gp transport activity from the
intracellular space, where P-gp accesses substrate. Characterizing P-gp transporter
kinetics directly from flux data would be simplifying the system as a single barrier with
only P-gp activity, which would only yield apparent kinetics for P-gp. In reality there are
several other kinetic processes contributing to flux across the monolayer, the most
important of which are described in our 3 compartmental model (42-47).
The physiological relevance of CLP-gp makes it appropriate for application in
physiologically-based pharmacokinetic (PBPK) models. These models, as we have
described, incorporate chemical information about compounds and physiological and in
vitro kinetic information into anatomically arranged compartments. Intrinsic clearance,
defined as the perfusion-rate-independent clearance of a drug from a system by the
cumulative intrinsic activities of the contributing drug metabolizing enzymes and/or
transporters, is an essential component of these models. For drug metabolizing enzymes,
intrinsic clearance can be characterized from the metabolism kinetics in isolated
hepatocyte, microsomal fractions, or recombinant enzyme systems (15; 48-50). For
uptake transporters, it can be described from uptake kinetics in isolated hepatocytes or
recombinant cell lines (51; 50). With the modeled clearance we describe here in our
study, we can produce the intrinsic clearance input for PBPK model efflux transporters
from the conventional monolayer permeability assay. In the context of a PBPK, which
incorporates all of the dynamically acting ADME proteins and physiological processes,
we can understand drugs that appear to interact with P-gp in the monolayer permeability
assay but do not necessarily demonstrate clinical P-gp interaction because of the
overlapping in vivo activity of other ADME enzymes (52).
3.6

Limitations of the experimental approach to estimate CLP-gp (model
assumptions)
1. All transwell transport experiments were assumed to operate exclusively under
linear conditions in our model.
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2. We assumed there were no spatial variations in pH or concentration intracellularly
3. Our steady state model of transport assumes mass balance of drug in the system,
when in fact drug is removed during multiple sampling
4. We assumed that digoxin is not subject to any significant metabolism
5. We assumed that neither digoxin, nor inulin were subject to any significant
protein or plastic binding in the transwells
6. We simplified the complexity of the model in order to successfully fit the data, by
assuming that digoxin clearance was equal in both directions across the apical
membrane and equal in both directions across the basolateral membrane.
3.7

Recommendations/future studies
1. In our studies, we investigated P-gp efflux with 2 commonly used monolayer cell
types (Caco-2 and LLCPK). In a future study, it would be interesting to include Pgp activity estimates made in MDCK/MDCK-MDR1 monolayers to the linear
regression analysis, to confirm that the validity and sensitivity of CLP-gp as a P-gp
metric extends to this third commonly used monolayer cell type.
2. Similarly, it would be interesting to include monolayer assays conducted with
varied protocols to the linear regression analysis, to see how well our model
isolates P-gp activity and accounts for monolayer difference produced by variable
laboratory practices.
3. We used the gold standard P-gp probe drug, digoxin, for our study, but future
studies may investigate Papp, EfR and CLP-gp monolayer permeability assay
metrics for other P-gp substrates that may show different permeability or may be
less specific to the P-gp transporter.
4. It would be interesting as well to consider effects of P-gp inhibition by drugs and
effects on P-gp activity metrics. For example, examining which activity metric is
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most sensitive in estimating the inhibitory constant (Ki) for P-gp for a given test
drug whose co-administration affects the flux of digoxin in a transwell system.
5. Finally, estimation of absolute P-gp intrinsic activity of P-gp with digoxin using
absolute quantification of P-gp by LC-MS/MS would provide critical information
for IVIVE.
3.8

Overall conclusion

In conclusion, our findings support our hypothesis that CLP-gp offers a more valid and
sensitive estimate of P-gp activity in the monolayer permeability assay, particularly for
comparison across different monolayer cell types. The traditional metrics, Papp and EfR
do not relate well across the many variations of monolayer permeability assay that exist
and thus the conclusions drawn by these metrics have limited global value. Conversely,
we found that modeled clearance, CLP-gp, seems to account for non-P-gp transcellular and
paracellular processes that contribute to monolayer transit, thus providing a more
physiologically relevant characterization of P-gp transporter activity. Many efflux
transporters, particularly P-glycoprotein, play an important role in drug pharmacokinetics
and disposition and in vitro characterization of P-gp activity is very important to
understanding drug PK and DDIs (30; 40; 41). Modeled clearance provides more
physiologically relevant information that can be used for understanding and predicting
clinical pharmacokinetics for more successful drug therapy.
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